{"filepath": "../L2M3_data/0_csd_related_papers/ACS_XML/mp400571a.xml", "publisher": "acs", "elements": [{"idx": 1, "type": "text", "classification": ["else"], "content": "<p>Current\nUnited States Food and Drug Administration (FDA)-approved\nlithium salts are plagued with a narrow therapeutic window. Recent\nattempts to find alternative drugs have identified new chemical entities,\nbut lithium\u2019s polypharmacological mechanisms for treating neuropsychiatric\ndisorders are highly debated and are not yet matched. Thus, re-engineering\ncurrent lithium solid forms in order to optimize performance represents\na low cost and low risk approach to the desired therapeutic outcome.\nIn this contribution, we employed a crystal engineering strategy to\nsynthesize the first ionic cocrystals (ICCs) of lithium salts with\norganic anions. We are unaware of any previous studies that have assessed\nthe biological efficacy of any ICCs, and encouragingly we found that\nthe new speciation did not negatively affect established bioactivities\nof lithium. We also observed that lithium ICCs exhibit modulated pharmacokinetics\ncompared to lithium carbonate. Indeed, the studies detailed herein\nrepresent an important advancement in a crystal engineering approach\nto a new generation of lithium therapeutics.</p>", "clean_text": "Current United States Food and Drug Administration (FDA)-approved lithium salts are plagued with a narrow therapeutic window. Recent attempts to find alternative drugs have identified new chemical entities, but lithium's polypharmacological mechanisms for treating neuropsychiatric disorders are highly debated and are not yet matched. Thus, re-engineering current lithium solid forms in order to optimize performance represents a low cost and low risk approach to the desired therapeutic outcome. In this contribution, we employed a crystal engineering strategy to synthesize the first ionic cocrystals (ICCs) of lithium salts with organic anions. We are unaware of any previous studies that have assessed the biological efficacy of any ICCs, and encouragingly we found that the new speciation did not negatively affect established bioactivities of lithium. We also observed that lithium ICCs exhibit modulated pharmacokinetics compared to lithium carbonate. Indeed, the studies detailed herein represent an important advancement in a crystal engineering approach to a new generation of lithium therapeutics.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 2, "type": "text", "classification": ["else"], "content": "<title>Introduction</title><p>Lithium\nsalts have a long history of human consumption beginning\nin the 1800s. In psychiatry, they have been used to treat mania and\nas a prophylactic for depression since the mid-20th century. Today, lithium salts are used as a mood stabilizer\nfor the treatment of bipolar disorder and also, off-label, for other\npsychiatric indications. For example, lithium is the only drug that\nconsistently reduces suicidality in patients with neuropsychiatric\ndisorders. Despite these effective medicinal uses, current United\nStates Food and Drug Administration (FDA)-approved lithium pharmaceutics\n(lithium carbonate and lithium citrate) are plagued with a narrow\ntherapeutic window that requires regular monitoring of plasma lithium\nlevels and blood chemistry by a clinician to mitigate adverse events.\nStill, many patients undergoing lithium therapy find the side effects\nto be unbearable, which negatively affects compliance and discourages\nphysicians from utilizing lithium. These problems arise because lithium\u2019s\nsite of action is the brain, and current lithium salts cross the blood-brain-barrier\nslowly. As a result, there is unnecessary accumulation\nof lithium ions in peripheral organs, particularly in the kidneys\nand heart, where side effects can arise. Thus, multiple administrations\nthroughout the day are required to safely reach therapeutic concentrations.\nFurther, the patient must remain keenly aware of their hydration status\nas dehydration promotes a more rapid serum chemical imbalance with\nrenal and cardiac toxicity. Unfortunately, the serum concentrations\nrequired to maintain therapeutic efficacy often lead to metabolic\nadverse effects such as hypothyroidism, hyperparathyroidism, weight\ngain, and nephrogenic diabetes insipidus. If supratherapeutic serum concentrations of lithium are achieved,\nlithium intoxication ensues. Patients with lithium poisoning can exhibit\nloss of consciousness, muscle tremor, epileptic seizures, and pulmonary\ncomplications. Left untreated, lithium\nintoxication can lead to death.</p>", "clean_text": "Introduction\n\nLithium salts have a long history of human consumption beginning in the 1800s. In psychiatry, they have been used to treat mania and as a prophylactic for depression since the mid-20th century. Today, lithium salts are used as a mood stabilizer for the treatment of bipolar disorder and also, off-label, for other psychiatric indications. For example, lithium is the only drug that consistently reduces suicidality in patients with neuropsychiatric disorders. Despite these effective medicinal uses, current United States Food and Drug Administration (FDA)-approved lithium pharmaceutics (lithium carbonate and lithium citrate) are plagued with a narrow therapeutic window that requires regular monitoring of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events. Still, many patients undergoing lithium therapy find the side effects to be unbearable, which negatively affects compliance and discourages physicians from utilizing lithium. These problems arise because lithium's site of action is the brain, and current lithium salts cross the blood-brain-barrier slowly. As a result, there is unnecessary accumulation of lithium ions in peripheral organs, particularly in the kidneys and heart, where side effects can arise. Thus, multiple administrations throughout the day are required to safely reach therapeutic concentrations. Further, the patient must remain keenly aware of their hydration status as dehydration promotes a more rapid serum chemical imbalance with renal and cardiac toxicity. Unfortunately, the serum concentrations required to maintain therapeutic efficacy often lead to metabolic adverse effects such as hypothyroidism, hyperparathyroidism, weight gain, and nephrogenic diabetes insipidus. If supratherapeutic serum concentrations of lithium are achieved, lithium intoxication ensues. Patients with lithium poisoning can exhibit loss of consciousness, muscle tremor, epileptic seizures, and pulmonary complications. Left untreated, lithium intoxication can lead to death.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 3, "type": "text", "classification": ["else"], "content": "<p>Because lithium is so effective\nat reducing manic episodes and\nsuicidality in patients with bipolar disorder, it is still used clinically\ndespite its narrow therapeutic index and serious side effects. This\nhas motivated a search for alternatives to lithium with similar bioactivities.\nThe problem with this approach is that the mechanism of action remains\nelusive. Nevertheless, recent studies have identified many important\nbioactivities of lithium that may be responsible for its therapeutic\nefficacy in its current FDA-approved indications and beyond. For example,\nlithium exerts neuroprotective effects, in part, by increasing brain-derived\nneurotrophic factor (BDNF). Chronic lithium treatment has been shown\nto increase the expression of BDNF in rats and humans. This increase in BDNF activity\ncan lead to restoration of learning and memory deficits through promotion\nof neurogenesis and long-term potentiation (LTP). Another neuroprotective\nmechanism of lithium is attenuation of the production of inflammatory\ncytokines like IL-6 and nitric oxide (NO) in activated microglia. This is particularly important since aberrant\nmicroglial function is a common finding in a number of neuropsychiatric\ndiseases. Moreover, recent lines of evidence\nhave implicated BDNF and NO in novel mechanisms for lithium\u2019s antidepressant\neffects.</p>", "clean_text": "Because lithium is so effective at reducing manic episodes and suicidality in patients with bipolar disorder, it is still used clinically despite its narrow therapeutic index and serious side effects. This has motivated a search for alternatives to lithium with similar bioactivities. The problem with this approach is that the mechanism of action remains elusive. Nevertheless, recent studies have identified many important bioactivities of lithium that may be responsible for its therapeutic efficacy in its current FDA-approved indications and beyond. For example, lithium exerts neuroprotective effects, in part, by increasing brain-derived neurotrophic factor (BDNF). Chronic lithium treatment has been shown to increase the expression of BDNF in rats and humans. This increase in BDNF activity can lead to restoration of learning and memory deficits through promotion of neurogenesis and long-term potentiation (LTP). Another neuroprotective mechanism of lithium is attenuation of the production of inflammatory cytokines like IL-6 and nitric oxide (NO) in activated microglia. This is particularly important since aberrant microglial function is a common finding in a number of neuropsychiatric diseases. Moreover, recent lines of evidence have implicated BDNF and NO in novel mechanisms for lithium's antidepressant effects.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 4, "type": "text", "classification": ["else"], "content": "<p>Lithium has also been found to inhibit certain enzymes\nin a noncompetitive\nmanner by displacing the required divalent cation, magnesium. Two of these enzymes that have important implications\nin bipolar disorder are glycogen synthase kinase-3 beta (GSK-3\u03b2)\nand inositol monophosphatase (IMPase). GSK-3\u03b2 was first identified\nas the molecular target of lithium by Klein and Melton. It functions by phosphorylating glycogen synthase,\nthe rate-limiting enzyme of glycogen biosynthesis. GSK-3\u03b2 inhibitors like lithium generally produce\nantidepressant-like and antimania-like effects in animal models, which\nhave been used to explain lithium\u2019s efficacy for bipolar disorder. GSK-3\u03b2 is expressed in all tissues, with\nparticularly abundant levels in the brain. Therefore, this enzyme is thought to have tremendous potential as\na therapeutic target for the treatment of a variety of neurological\ndiseases that are characterized by dysregulated GSK-3\u03b2 such\nas Alzheimer\u2019s disease, HIV associated neurocognitive disorders,\nand autism spectrum disorders.\n</p>", "clean_text": "Lithium has also been found to inhibit certain enzymes in a noncompetitive manner by displacing the required divalent cation, magnesium. Two of these enzymes that have important implications in bipolar disorder are glycogen synthase kinase-3 beta (GSK-3\u03b2) and inositol monophosphatase (IMPase). GSK-3\u03b2 was first identified as the molecular target of lithium by Klein and Melton. It functions by phosphorylating glycogen synthase, the rate-limiting enzyme of glycogen biosynthesis. GSK-3\u03b2 inhibitors like lithium generally produce antidepressant-like and antimania-like effects in animal models, which have been used to explain lithium's efficacy for bipolar disorder. GSK-3\u03b2 is expressed in all tissues, with particularly abundant levels in the brain. Therefore, this enzyme is thought to have tremendous potential as a therapeutic target for the treatment of a variety of neurological diseases that are characterized by dysregulated GSK-3\u03b2 such as Alzheimer's disease, HIV associated neurocognitive disorders, and autism spectrum disorders. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 5, "type": "text", "classification": ["else"], "content": "<p>In addition to inhibiting\nGSK-3\u03b2, lithium also inhibits inositol\nmonophosphatase (IMPase) leading to cerebral inositol depletion. Lithium, valproic acid, and carbamazepine, which are all used for\nstabilization of mood, have been shown to lead to the depletion of\ninositol. This has bolstered support\nfor the inositol depletion hypothesis of lithium therapy and has highlighted\nthis molecular target in the search for \u201clithium mimetics\u201d. However, given the frequency of suicidality\nas a comorbidity in patients with bipolar disorder and that only lithium consistently reduces suicidality in these\npatients, it is doubtful that selective IMPase inhibitors will produce\nthe desired clinical outcome that can be achieved with lithium. These\nlines of evidence imply that the antisuicidality effects of lithium\nare not solely attributable to IMPase inhibition/inositol depletion.</p>", "clean_text": "In addition to inhibiting GSK-3\u03b2, lithium also inhibits inositol monophosphatase (IMPase) leading to cerebral inositol depletion. Lithium, valproic acid, and carbamazepine, which are all used for stabilization of mood, have been shown to lead to the depletion of inositol. This has bolstered support for the inositol depletion hypothesis of lithium therapy and has highlighted this molecular target in the search for \"lithium mimetics\". However, given the frequency of suicidality as a comorbidity in patients with bipolar disorder and that only lithium consistently reduces suicidality in these patients, it is doubtful that selective IMPase inhibitors will produce the desired clinical outcome that can be achieved with lithium. These lines of evidence imply that the antisuicidality effects of lithium are not solely attributable to IMPase inhibition/inositol depletion.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 6, "type": "text", "classification": ["else"], "content": "<p>That the solid-state structure and composition of an active pharmaceutical\ningredient (API) critically impacts its drug delivery performance,\nespecially its physicochemical properties, means that materials science\nplays a critical role in enabling the development of bioactive molecules\nas drug products. In this contribution, we report that a materials\nscience strategy based upon crystal engineering can enable improvement\nof the therapeutic window of lithium while retaining the bioactivities\nof current FDA-approved lithium solid forms. Our approach is based\nupon cocrystallization, which has gained the attention of both academia\nand industry in the past decade. Indeed, the FDA has recently released\nregulatory guidelines for industry on pharmaceutical cocrystals. Almarsson and Zaworotko have defined pharmaceutical\ncocrystals as \u201cco-crystals that are formed between a molecular\nor ionic active pharmaceutical ingredient (API) and a co-crystal former\nthat is a solid under ambient conditions\u201d. Cocrystallization is of growing interest because these\nmulticomponent materials that are based upon two or more \u201ccoformers\u201d\ncan be rationally designed by crystal engineering. Further, they represent novel solid forms of APIs that can improve\nthe physicochemical properties (e.g., solubility and stability), improve\nefficacy (e.g., bioavailability), and provide a means for extending\nthe life cycle of existing APIs.\n</p>", "clean_text": "That the solid-state structure and composition of an active pharmaceutical ingredient (API) critically impacts its drug delivery performance, especially its physicochemical properties, means that materials science plays a critical role in enabling the development of bioactive molecules as drug products. In this contribution, we report that a materials science strategy based upon crystal engineering can enable improvement of the therapeutic window of lithium while retaining the bioactivities of current FDA-approved lithium solid forms. Our approach is based upon cocrystallization, which has gained the attention of both academia and industry in the past decade. Indeed, the FDA has recently released regulatory guidelines for industry on pharmaceutical cocrystals. Almarsson and Zaworotko have defined pharmaceutical cocrystals as \"co-crystals that are formed between a molecular or ionic active pharmaceutical ingredient (API) and a co-crystal former that is a solid under ambient conditions\". Cocrystallization is of growing interest because these multicomponent materials that are based upon two or more \"coformers\" can be rationally designed by crystal engineering. Further, they represent novel solid forms of APIs that can improve the physicochemical properties (e.g., solubility and stability), improve efficacy (e.g., bioavailability), and provide a means for extending the life cycle of existing APIs. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 7, "type": "text", "classification": ["else"], "content": "<p>Previously, we successfully used cocrystallization of two molecular\ncoformers to improve the solubility and consequent bioavailability\nof the poorly soluble bioflavonoid quercetin and to conversely lower the pharmacokinetics of the highly soluble\nantioxidant epigallocatechin-3-gallate, EGCG. The molecular cocrystals of quercetin and EGCG that we studied were\nstabilized by hydrogen bonded supramolecular synthons, which are assumed\nto dissociate <italic toggle=\"yes\">in vivo</italic> leaving therapeutically bioactive\nquercetin and EGCG. Ionic cocrystals (ICCs) have even more recently\nemerged as another class of multicomponent pharmaceutical materials\n(MPMs) of scientific and practical interest. ICCs can be defined as \u201cMPMs formed from a\nsalt and a molecular or ionic compound.\u201d The general formula\nof ICCs is therefore A<sup>+</sup>B<sup>\u2013</sup>N, where A<sup>+</sup> is a cation, B<sup>\u2013</sup> is an anion, and N is neutral\nmolecule or another salt. If one of the components of the ICC is a\npharmaceutical compound then there is considerable opportunity to\nmodulate the physicochemical and biological efficacy of the pharmaceutical\ncompound because there are two components that can be changed. This\ncontrasts with single component crystals of pharmaceutical compounds,\nwhich have very limited opportunities for fine-tuning of materials\nproperties, and other MPMs such as simple salts, A<sup>+</sup>B<sup>\u2013</sup>, and molecular cocrystals, AB, for which there is\nonly variable component besides the pharmaceutical compound.</p>", "clean_text": "Previously, we successfully used cocrystallization of two molecular coformers to improve the solubility and consequent bioavailability of the poorly soluble bioflavonoid quercetin and to conversely lower the pharmacokinetics of the highly soluble antioxidant epigallocatechin-3-gallate, EGCG. The molecular cocrystals of quercetin and EGCG that we studied were stabilized by hydrogen bonded supramolecular synthons, which are assumed to dissociate in vivo leaving therapeutically bioactive quercetin and EGCG. Ionic cocrystals (ICCs) have even more recently emerged as another class of multicomponent pharmaceutical materials (MPMs) of scientific and practical interest. ICCs can be defined as \"MPMs formed from a salt and a molecular or ionic compound.\" The general formula of ICCs is therefore A+B-N, where A+ is a cation, B- is an anion, and N is neutral molecule or another salt. If one of the components of the ICC is a pharmaceutical compound then there is considerable opportunity to modulate the physicochemical and biological efficacy of the pharmaceutical compound because there are two components that can be changed. This contrasts with single component crystals of pharmaceutical compounds, which have very limited opportunities for fine-tuning of materials properties, and other MPMs such as simple salts, A+B-, and molecular cocrystals, AB, for which there is only variable component besides the pharmaceutical compound.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 8, "type": "text", "classification": ["else"], "content": "<p>Zaworotko et al. reported ICCs of inorganic lithium salts, Li<sup>+</sup>B<sup>\u2013</sup>, with a series of amino acids, zwitterionic\nmolecules, N, by exploiting the strength of lithium carboxylate bonds. In these ICCs, the lithium cation (API) forms\ncoordination bonds to the amino acid coformers and the inorganic anions\nremain in the composition to balance charge. Given that coordination\nbonds are stronger than hydrogen bonds we became interested in determining\nif the stronger bonding would affect the <italic toggle=\"yes\">in vivo</italic> speciation\nof lithium and thereby modulate its therapeutic bioactivity and pharmacokinetics.\nWe herein describe the synthesis of two novel ICCs of organic anion\nsalts of lithium with the amino acid coformer, proline. We assessed\nthe blood and brain pharmacokinetics of this new speciation of lithium\nin rats and their therapeutic activities at several established targets\nof lithium therapy.</p>", "clean_text": "Zaworotko et al. reported ICCs of inorganic lithium salts, Li+B-, with a series of amino acids, zwitterionic molecules, N, by exploiting the strength of lithium carboxylate bonds. In these ICCs, the lithium cation (API) forms coordination bonds to the amino acid coformers and the inorganic anions remain in the composition to balance charge. Given that coordination bonds are stronger than hydrogen bonds we became interested in determining if the stronger bonding would affect the in vivo speciation of lithium and thereby modulate its therapeutic bioactivity and pharmacokinetics. We herein describe the synthesis of two novel ICCs of organic anion salts of lithium with the amino acid coformer, proline. We assessed the blood and brain pharmacokinetics of this new speciation of lithium in rats and their therapeutic activities at several established targets of lithium therapy.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 9, "type": "text", "classification": ["else"], "content": "<title>Experimental Section</title><title>Reagents and Materials</title><p>Lithium salicylate (\u226598%\npurity), lithium hydroxide (\u226598% purity), nicotinic acid (\u226598%\npurity), and proline (\u226599% purity) were purchased from Sigma-Aldrich\nCorporation (St. Louis, MO) and used as such without further purification.</p>", "clean_text": "Experimental Section\n\nReagents and Materials\n\nLithium salicylate (\u226598% purity), lithium hydroxide (\u226598% purity), nicotinic acid (\u226598% purity), and proline (\u226599% purity) were purchased from Sigma-Aldrich Corporation (St. Louis, MO) and used as such without further purification.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 10, "type": "text", "classification": ["synthesis condition"], "content": "<title>Lithium Cocrystal Syntheses</title><title>LISPRO</title><p>Lithium salicylate (\u226598%\npure, anhydrous,\nused as received from Sigma Aldrich, 1 mmol) and <sc>l</sc>-proline\n(\u226599% pure, used as received from Sigma Aldrich, 1 mmol) were\ndissolved in 2.0 mL of hot deionized water. The resulting solution\nwas maintained on a hot plate (75\u201390 \u00b0C) to allow slow\nevaporation of solvent until crystals had formed. Colorless crystals\nof LISPRO were collected.</p>", "clean_text": "Lithium Cocrystal Syntheses\n\nLISPRO\n\nLithium salicylate (\u226598% pure, anhydrous, used as received from Sigma Aldrich, 1 mmol) and l-proline (\u226599% pure, used as received from Sigma Aldrich, 1 mmol) were dissolved in 2.0 mL of hot deionized water. The resulting solution was maintained on a hot plate (75-90 \u00b0C) to allow slow evaporation of solvent until crystals had formed. Colorless crystals of LISPRO were collected.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['synthesis condition']"}}, {"idx": 11, "type": "text", "classification": ["synthesis condition"], "content": "<title>LNAPRO</title><p>Lithium hydroxide (\u226598%\npure, anhydrous,\nused as received from Sigma Aldrich, 1 mmol), nicotinic acid (\u226598%\npure, anhydrous, used as received from Sigma Aldrich, 1 mmol), and <sc>l</sc>-proline (\u226599% pure, used as received from Sigma Aldrich,\n2 mmol) were dissolved in 3.0 mL of deionized water and left to stand\non a hot plate until block shape colorless crystals had emerged from\nsolution.\n</p>", "clean_text": "LNAPRO\n\nLithium hydroxide (\u226598% pure, anhydrous, used as received from Sigma Aldrich, 1 mmol), nicotinic acid (\u226598% pure, anhydrous, used as received from Sigma Aldrich, 1 mmol), and l-proline (\u226599% pure, used as received from Sigma Aldrich, 2 mmol) were dissolved in 3.0 mL of deionized water and left to stand on a hot plate until block shape colorless crystals had emerged from solution. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['synthesis condition']"}}, {"idx": 12, "type": "figure", "classification": null, "content": "<fig id=\"fig1\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Reaction diagrams. Reactions for LISPRO (A)\nand LNAPRO (B).</p>\n</caption>\n<graphic id=\"gr1\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0009.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 1  Reaction diagrams. Reactions for LISPRO (A) and LNAPRO (B).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 13, "type": "text", "classification": ["else"], "content": "<title>Single-Crystal X-ray Data\nCollection and Structure Determinations</title><p>The X-ray diffraction\ndata were collected using a Bruker-AXS SMART-APEXII\nCCD diffractometer (Cu K\u03b1, \u03bb = 1.54178 \u00c5). Indexing\nwas performed using <italic toggle=\"yes\">APEX2</italic>\n (Difference Vectors method). Data integration and reduction were\nperformed using SaintPlus 6.01. Absorption\ncorrection was performed by multiscan method implemented in SADABS. Space groups were determined using XPREP implemented\nin APEX2. The structure was solved using\nSHELXS-97 (direct methods) and refined using SHELXL-97 (full-matrix\nleast-squares on F<sup>2</sup>) contained in OLEX2 and WinGX v1.70.01 programs.</p>", "clean_text": "Single-Crystal X-ray Data Collection and Structure Determinations\n\nThe X-ray diffraction data were collected using a Bruker-AXS SMART-APEXII CCD diffractometer (Cu K\u03b1, \u03bb = 1.54178 \u00c5). Indexing was performed using APEX2  (Difference Vectors method). Data integration and reduction were performed using SaintPlus 6.01. Absorption correction was performed by multiscan method implemented in SADABS. Space groups were determined using XPREP implemented in APEX2. The structure was solved using SHELXS-97 (direct methods) and refined using SHELXL-97 (full-matrix least-squares on F2) contained in OLEX2 and WinGX v1.70.01 programs.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 14, "type": "text", "classification": ["else"], "content": "<title>LISPRO</title><p>All non-hydrogen atoms, except\ndisordered C29a\nand C29b, were refined anisotropically. Hydrogen atoms of \u2212CH,\n\u2212CH2, \u2212NH2, and \u2212OH groups were placed in geometrically\ncalculated positions and included in the refinement process using\nriding model with isotropic thermal parameters: Uiso\u00ad(H) = 1.2Ueq (\u2212CH,\n\u2212CH2, \u2212NH2), Uiso\u00ad(H) = 1.5Ueq\u00ad(\u2212OH). One of the <sc>l</sc>-proline rings is disordered over two positions in a 1:1 ratio.\nSADI commands were used to restrain distances between disordered carbon\natoms. The crystal was a twin, and refinement was conducted with an\nHKL5 type file generated using the [\u22121/0/0;0/\u20131/0;0.14/0/1]\ntwin law. This corresponds to 180\u00b0 rotation about the [001] reciprocal\nlattice direction. Crystallographic data is available in the Cambridge\nStructural Database (CCDC 962323). The structure with probability\nellipsoids is available in the  (Figure S4).</p>", "clean_text": "LISPRO\n\nAll non-hydrogen atoms, except disordered C29a and C29b, were refined anisotropically. Hydrogen atoms of -CH, -CH2, -NH2, and -OH groups were placed in geometrically calculated positions and included in the refinement process using riding model with isotropic thermal parameters: Uiso(H) = 1.2Ueq (-CH, -CH2, -NH2), Uiso(H) = 1.5Ueq(-OH). One of the l-proline rings is disordered over two positions in a 1:1 ratio. SADI commands were used to restrain distances between disordered carbon atoms. The crystal was a twin, and refinement was conducted with an HKL5 type file generated using the [-1/0/0;0/-1/0;0.14/0/1] twin law. This corresponds to 180\u00b0 rotation about the [001] reciprocal lattice direction. Crystallographic data is available in the Cambridge Structural Database (CCDC 962323). The structure with probability ellipsoids is available in the  (Figure S4).", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 15, "type": "text", "classification": ["else"], "content": "<title>LNAPRO</title><p>All non-hydrogen atoms were\nrefined anisotropically.\nHydrogen atoms of the \u2212CH and \u2212CH<sub>2</sub> groups\nwere placed in geometrically calculated positions and included in\nthe refinement process using riding model with isotropic thermal parameters:\nUiso\u00ad(H) = 1.2Ueq (\u2212CH, \u2212CH<sub>2</sub>, \u2212NH<sub>2</sub>). Hydrogen atoms of the \u2212NH<sub>2</sub> group were\nfound from difference Fourier map inspection and were freely refined.\nCrystal data and refinement conditions are shown in Table . The <sc>l</sc>-proline ring was found to be disordered\nover two positions with an approximate ratio of 0.7:0.3. Crystallographic\ndata is available in the Cambridge Structural Database (CCDC 962324).\nThe structure with probability ellipsoids is available in the  (Figure S2).</p>", "clean_text": "LNAPRO\n\nAll non-hydrogen atoms were refined anisotropically. Hydrogen atoms of the -CH and -CH2 groups were placed in geometrically calculated positions and included in the refinement process using riding model with isotropic thermal parameters: Uiso(H) = 1.2Ueq (-CH, -CH2, -NH2). Hydrogen atoms of the -NH2 group were found from difference Fourier map inspection and were freely refined. Crystal data and refinement conditions are shown in Table . The l-proline ring was found to be disordered over two positions with an approximate ratio of 0.7:0.3. Crystallographic data is available in the Cambridge Structural Database (CCDC 962324). The structure with probability ellipsoids is available in the  (Figure S2).", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 16, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl1\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Crystallographic Data and Structure\nRefinement Parameters</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"3\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col3\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\">LISPRO</oasis:entry>\n<oasis:entry align=\"center\">LNAPRO</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>formula</oasis:entry>\n<oasis:entry>C<sub>12</sub>H<sub>14</sub>LiNO<sub>5</sub>\n</oasis:entry>\n<oasis:entry>C<sub>11</sub>H<sub>13</sub>LiN<sub>2</sub>O<sub>4</sub>\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>MW</oasis:entry>\n<oasis:entry>259.18</oasis:entry>\n<oasis:entry>244.17</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>crystal system</oasis:entry>\n<oasis:entry>monoclinic</oasis:entry>\n<oasis:entry>orthorhombic</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>space group</oasis:entry>\n<oasis:entry>\n<italic toggle=\"yes\">P</italic>2<sub>1</sub>\n</oasis:entry>\n<oasis:entry>\n<italic toggle=\"yes\">P</italic>2<sub>1</sub>2<sub>1</sub>2</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">a</italic> (\u00c5)</oasis:entry>\n<oasis:entry>10.3601(19)</oasis:entry>\n<oasis:entry>10.2156(2)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">b</italic> (\u00c5)</oasis:entry>\n<oasis:entry>10.1556(16)</oasis:entry>\n<oasis:entry>10.4646(3)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">c</italic> (\u00c5)</oasis:entry>\n<oasis:entry>12.173(3)</oasis:entry>\n<oasis:entry>11.3811(3)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b1 (deg)</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b2 (deg)</oasis:entry>\n<oasis:entry>93.415(11)</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b3 (deg)</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">V</italic> (\u00c5<sup>3</sup>)</oasis:entry>\n<oasis:entry>1278.5(4)</oasis:entry>\n<oasis:entry>1216.66(5)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">D</italic>\n<sub>c</sub> (mg\u00a0m<sup>\u20113</sup>)</oasis:entry>\n<oasis:entry>1.347</oasis:entry>\n<oasis:entry>1.333</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">Z</italic>\n</oasis:entry>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>4</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2\u03b8 range</oasis:entry>\n<oasis:entry>7.28\u2013131.94\u00b0</oasis:entry>\n<oasis:entry>7.76\u2013131.9\u00b0</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">N</italic>\n<sub>ref</sub>/<italic toggle=\"yes\">N</italic>\n<sub>para</sub>\n</oasis:entry>\n<oasis:entry>6896/352</oasis:entry>\n<oasis:entry>2116/183</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">T</italic>  (K)</oasis:entry>\n<oasis:entry>228(2)</oasis:entry>\n<oasis:entry>228(2)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>R<sub>1</sub> [<italic toggle=\"yes\">I</italic>\u00a0&gt;\u00a02\u03c3(<italic toggle=\"yes\">I</italic>)]</oasis:entry>\n<oasis:entry>0.0394</oasis:entry>\n<oasis:entry>0.0394</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">w</italic>R<sub>2</sub>\n</oasis:entry>\n<oasis:entry>0.0935</oasis:entry>\n<oasis:entry>0.0935</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>GOF</oasis:entry>\n<oasis:entry>0.988</oasis:entry>\n<oasis:entry>0.988</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>abs coef.</oasis:entry>\n<oasis:entry>0.872</oasis:entry>\n<oasis:entry>0.843</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 17, "type": "text", "classification": ["else"], "content": "<title>Purity Confirmation</title><p>Powder X-ray diffraction (PXRD)\nand differential scanning calorimetry (DSC) were used to confirm the\npurity of the cocrystal preparations. PXRD patterns (from bulk samples)\nwere compared to the calculated pattern (from the single crystal)\nand indicated that phase purity had been obtained (Figure \n). DSC indicated a clean single\nendotherm corresponding to the cocrystals. Prior to bioactivity and\npharmacokinetics evaluation, purity was confirmed by preparing equimolar\nlithium solutions of LISPRO and LIS and measuring lithium concentration\nusing atomic absorption spectrometry. The DSC (Figure S1) for LNAPRO\nis available in the . The DSC (Figure S3) and AAS (Figure S5) data for LISPRO are available\nin the .</p>", "clean_text": "Purity Confirmation\n\nPowder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC) were used to confirm the purity of the cocrystal preparations. PXRD patterns (from bulk samples) were compared to the calculated pattern (from the single crystal) and indicated that phase purity had been obtained (Figure  ). DSC indicated a clean single endotherm corresponding to the cocrystals. Prior to bioactivity and pharmacokinetics evaluation, purity was confirmed by preparing equimolar lithium solutions of LISPRO and LIS and measuring lithium concentration using atomic absorption spectrometry. The DSC (Figure S1) for LNAPRO is available in the . The DSC (Figure S3) and AAS (Figure S5) data for LISPRO are available in the .", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 18, "type": "figure", "classification": null, "content": "<fig id=\"fig2\" orientation=\"portrait\" position=\"float\">\n<label>2</label>\n<caption>\n<p>Crystal packing\nin LISPRO and LNAPRO. Square grid network exhibited\nby LISPRO (A) and LNAPRO (B). Hydrogen atoms are removed for clarity.</p>\n</caption>\n<graphic id=\"gr2\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0010.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 2  Crystal packing in LISPRO and LNAPRO. Square grid network exhibited by LISPRO (A) and LNAPRO (B). Hydrogen atoms are removed for clarity.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 19, "type": "figure", "classification": null, "content": "<fig id=\"fig3\" orientation=\"portrait\" position=\"float\">\n<label>3</label>\n<caption>\n<p>Powder X-ray diffraction patterns of LISPRO\nand LNAPRO. Experimental\nversus calculated PXRD of LISPRO (A) and LNAPRO (B).</p>\n</caption>\n<graphic id=\"gr3\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0001.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 3  Powder X-ray diffraction patterns of LISPRO and LNAPRO. Experimental versus calculated PXRD of LISPRO (A) and LNAPRO (B).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 20, "type": "text", "classification": ["else"], "content": "<title>GSK-3\u03b2 Studies</title><p>Adult rat hippocampal\nneural stem\ncells (NSC, Millipore) were treated with LISPRO or LIS at 0, 1, and\n5 mM for 40 h in a differentiation media. Cells were lysed using RIPA\nbuffer with protease inhibitors cocktail and subjected to immunoblotting\nanalysis using an antibody against phosphorylated phospho-GSK-3\u03b2Ser9\n(inactive form) or total GSK-3\u03b2. Densitometry analysis was represented\nby ratio of phospho-GSK-3\u03b2Ser9 to total GSK-3\u03b2 band intensity\nunder WB from two independent experiments. <italic toggle=\"yes\">t</italic>-tests\nwere used to assess statistical significance in the ratio of phospho-GSK-3\u03b2Ser9\nto total GSK-3\u03b2.</p>", "clean_text": "GSK-3\u03b2 Studies\n\nAdult rat hippocampal neural stem cells (NSC, Millipore) were treated with LISPRO or LIS at 0, 1, and 5 mM for 40 h in a differentiation media. Cells were lysed using RIPA buffer with protease inhibitors cocktail and subjected to immunoblotting analysis using an antibody against phosphorylated phospho-GSK-3\u03b2Ser9 (inactive form) or total GSK-3\u03b2. Densitometry analysis was represented by ratio of phospho-GSK-3\u03b2Ser9 to total GSK-3\u03b2 band intensity under WB from two independent experiments. t-tests were used to assess statistical significance in the ratio of phospho-GSK-3\u03b2Ser9 to total GSK-3\u03b2.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 21, "type": "text", "classification": ["else"], "content": "<title>BDNF Studies</title><p>Mouse neuroblastoma\n(N2a) cells were grown\nin Dulbecco\u2019s modified Eagle\u2019s medium (DMEM) supplemented\nwith 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.\nCells were plated in 24-well plate at a density 5 \u00d7 10<sup>4</sup> cells per well in DMEM supplemented with 5% FBS and 1% penicillin-streptomycin.\nTwenty-four hours later, 1 and 10 mM of lithium as lithium salicylate\n(LIS) or cocrystal (LISPRO) were added to each well and incubated\nfor 48 h. After treatment, media were collected for brain derived\nneurotrophic factor (BDNF) enzyme linked immunosorbent assay (ELISA)\nand cells were lysed for bicinchoninic acid assay (BCA). BDNF levels\nwere measured in collected media with a BDNF Sandwich ELISA Kit (Millipore,\ncat. no. CYT306). Shortly, samples were incubated in a mouse anti-BDNF\nmonoclconal antibody coated 96-well immunoassay plate at 4 \u00b0C,\novernight on a shaker. The plates were thoroughly washed at least\nfour times, and a biotinylated mouse anti-human BDNF monoclonal antibody\nwas added to each well and incubated for 2.5 h at room temperature\non a shaker. After washing, a streptavidin-enzyme conjugate solution\nwas added and incubated at room temperature for 1 h on a shaker. After\nwashing, a TMB/E substrate solution was added to the plates and inactivated\nafter 7 min by adding the stop solution. The BDNF was detected immediately\nby measuring absorbance at 450 nm using a microplate reader. BDNF\nconcentration was analyzed based on the BDNF standard curve and normalized\nto total protein concentration as determined using a BCA protein assay\nkit (Pierce, Rockford, IL).</p>", "clean_text": "BDNF Studies\n\nMouse neuroblastoma (N2a) cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were plated in 24-well plate at a density 5 \u00d7 104 cells per well in DMEM supplemented with 5% FBS and 1% penicillin-streptomycin. Twenty-four hours later, 1 and 10 mM of lithium as lithium salicylate (LIS) or cocrystal (LISPRO) were added to each well and incubated for 48 h. After treatment, media were collected for brain derived neurotrophic factor (BDNF) enzyme linked immunosorbent assay (ELISA) and cells were lysed for bicinchoninic acid assay (BCA). BDNF levels were measured in collected media with a BDNF Sandwich ELISA Kit (Millipore, cat. no. CYT306). Shortly, samples were incubated in a mouse anti-BDNF monoclconal antibody coated 96-well immunoassay plate at 4 \u00b0C, overnight on a shaker. The plates were thoroughly washed at least four times, and a biotinylated mouse anti-human BDNF monoclonal antibody was added to each well and incubated for 2.5 h at room temperature on a shaker. After washing, a streptavidin-enzyme conjugate solution was added and incubated at room temperature for 1 h on a shaker. After washing, a TMB/E substrate solution was added to the plates and inactivated after 7 min by adding the stop solution. The BDNF was detected immediately by measuring absorbance at 450 nm using a microplate reader. BDNF concentration was analyzed based on the BDNF standard curve and normalized to total protein concentration as determined using a BCA protein assay kit (Pierce, Rockford, IL).", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 22, "type": "text", "classification": ["else"], "content": "<title>LPS-Activated Microglia Studies</title><p>BV2 microglia cells\nwere grown in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin.\nCells were plated in 24-well plate at a density 5 \u00d7 10<sup>4</sup> cells per well in DMEM with 10% FBS and 1% penicillin-streptomycin.\nTwenty-four hours later, 25 and 12.5 mM of lithium in DMEM as LIS\nor LISPRO were added to each wells and incubated for 30 min. The microglia\nwere activated by the addition of 100 ng/mL or LPS. Six hours later,\nmedia was collected and NO was measured using a Griess Reagent system\n(Promega, Madison, WI) per the manufacturer\u2019s instructions.</p>", "clean_text": "LPS-Activated Microglia Studies\n\nBV2 microglia cells were grown in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were plated in 24-well plate at a density 5 \u00d7 104 cells per well in DMEM with 10% FBS and 1% penicillin-streptomycin. Twenty-four hours later, 25 and 12.5 mM of lithium in DMEM as LIS or LISPRO were added to each wells and incubated for 30 min. The microglia were activated by the addition of 100 ng/mL or LPS. Six hours later, media was collected and NO was measured using a Griess Reagent system (Promega, Madison, WI) per the manufacturer's instructions.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 23, "type": "text", "classification": ["else"], "content": "<title>Neuronal Differentiation Studies</title><p>Adult rat hippocampal\nneural stem cells were obtained from Millipore (Billerica, MA) and\ngrown in expansion media that contained 1\u00d7 B-27 supplement minus\nvitamin A, 2 mM Gibco GlutaMAX, and 20 ng/mL bFGF in Neurobasal A\nmedium (all from Gibco, Carlsbad, CA). After neurospheres formed,\ncells were plated on 12 mm poly-<sc>l</sc>-lysine coated coverslips\n(BD Biocoat, Bedford, MA) at density 5 \u00d7 10<sup>4</sup> cells/well\nin 3 mM LIS and LISPRO containing Neurobasal A medium only. Differentiation\nwas induced for 5 days at 37 \u00b0C with 5% CO<sub>2</sub>, and equal\namounts of media was added to each well at day 3.</p>", "clean_text": "Neuronal Differentiation Studies\n\nAdult rat hippocampal neural stem cells were obtained from Millipore (Billerica, MA) and grown in expansion media that contained 1\u00d7 B-27 supplement minus vitamin A, 2 mM Gibco GlutaMAX, and 20 ng/mL bFGF in Neurobasal A medium (all from Gibco, Carlsbad, CA). After neurospheres formed, cells were plated on 12 mm poly-l-lysine coated coverslips (BD Biocoat, Bedford, MA) at density 5 \u00d7 104 cells/well in 3 mM LIS and LISPRO containing Neurobasal A medium only. Differentiation was induced for 5 days at 37 \u00b0C with 5% CO2, and equal amounts of media was added to each well at day 3.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 24, "type": "text", "classification": ["else"], "content": "<title>Immunocytochemistry</title><p>Cells were fixed with 4% paraformaldehyde\n(PFA, Sigma-Aldrich, St. Louis, MO) for 15 min at room temperature\nand washed with PBS for 5 min three times. Cells were then permeabilized\nwith 1% Triton X-100 in PBS for 10 min at room temperature. After\nwashing with PBS for 5 min three times, cells were blocked with 1%\nbovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) in 0.02%\nTween 20 containing PBS (PBST) for 10 min at room temperature with\ngentle shaking. Mouse monoclonal anti-Tuj1 (Covance, MMS 435P, 1:2000)\nand rabbit polyclonal anti-GFAP (Abcam, ab7260, 1:1000) antibodies\nwere diluted in the blocking buffer and incubated for overnight at\n4 \u00b0C with gentle shaking. After washing with 0.02% PBST 5 min\nfor three times, goat anti-mounse Alexa Fluor 488 (1:250, green) and\ngoat anti-rabbit Alexa Fluor conjugated 555 (1:250, red) (both from\nAbcam, Cambridge, MA) in blocking buffer were incubated for 45 min\nat room temperature. Nuclei were visualized by mounting with VECTASHEILD\nhardset mounting media with DAPI (Vector laboratory, Burlingame, CA).\nFluorescence images were obtained by using a Zeiss microscope at 20\u00d7\nmagnification. Scale bar = 20 \u03bcm.</p>", "clean_text": "Immunocytochemistry\n\nCells were fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich, St. Louis, MO) for 15 min at room temperature and washed with PBS for 5 min three times. Cells were then permeabilized with 1% Triton X-100 in PBS for 10 min at room temperature. After washing with PBS for 5 min three times, cells were blocked with 1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO) in 0.02% Tween 20 containing PBS (PBST) for 10 min at room temperature with gentle shaking. Mouse monoclonal anti-Tuj1 (Covance, MMS 435P, 1:2000) and rabbit polyclonal anti-GFAP (Abcam, ab7260, 1:1000) antibodies were diluted in the blocking buffer and incubated for overnight at 4 \u00b0C with gentle shaking. After washing with 0.02% PBST 5 min for three times, goat anti-mounse Alexa Fluor 488 (1:250, green) and goat anti-rabbit Alexa Fluor conjugated 555 (1:250, red) (both from Abcam, Cambridge, MA) in blocking buffer were incubated for 45 min at room temperature. Nuclei were visualized by mounting with VECTASHEILD hardset mounting media with DAPI (Vector laboratory, Burlingame, CA). Fluorescence images were obtained by using a Zeiss microscope at 20\u00d7 magnification. Scale bar = 20 \u03bcm.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 25, "type": "text", "classification": "error", "content": "<title>Pharmacokinetics Studies</title><p>Male Sprague\u2013Dawley\nrats weighing 200\u2013250 g were purchased from Harlan. The animals\nwere housed at the Moffitt Cancer Center vivarium (Tampa, FL) with\na 12 h light\u2013dark cycle. The rats were allowed to acclimate\nfor a period of one week before any experiments are carried out. All\nexperiments were conducted in accordance with USF IACUC approved protocols.\nThey were allowed free access to food and water throughout the experiment.\nThe rats were dosed via oral gavage with 4 mEq/kg elemental lithium\nas LISPRO or Li<sub>2</sub>CO<sub>3</sub> dissolved in deionized water\nor suspended in 1% methylcellulose, respectively. Animals in each\ntreatment group were euthanized at 2, 24, 48, and 72 h (<italic toggle=\"yes\">n</italic> = 3/time point), and blood was collected by cardiac puncture and\ncarefully perfused with a pressure-controlled pump to maintain microvasculature\nintegrity before removing brain tissue. Blood was centrifuged at 1600<italic toggle=\"yes\">g</italic> at room temperature for 10 min, and plasma was separated.\nA 500 \u03bcL aliquot was diluted 10-fold in a 5% TCA and 10% IPA\nsolution, vortexed, and allowed to sit for 10 min in order to precipitate\nproteins. These aliquots were centrifuged at 3000<italic toggle=\"yes\">g</italic> for 30 min, and the supernatant was transferred to clean tubes prior\nto measuring lithium content using atomic absorption spectroscopy\n(AAS). Brains were rinsed with PBS and weighed, and then an equal\nvolume of concentrated HNO<sub>3</sub> was added. The brains were\nheated in this nitric acid solution for 1 h, allowed to cool to room\ntemperature, and then centrifuged at 3000<italic toggle=\"yes\">g</italic> for 1\nh. The supernatant was removed and diluted 10-fold in 10% IPA prior\nto measuring lithium content using AAS (Shimadzu AA-6200). Peak height\nmeasurements were carried out referring to values obtained for standards\nof known concentrations. Lithium measurements are plotted as mean\n\u00b1 SEM.</p>", "clean_text": "Pharmacokinetics Studies\n\nMale Sprague-Dawley rats weighing 200-250 g were purchased from Harlan. The animals were housed at the Moffitt Cancer Center vivarium (Tampa, FL) with a 12 h light-dark cycle. The rats were allowed to acclimate for a period of one week before any experiments are carried out. All experiments were conducted in accordance with USF IACUC approved protocols. They were allowed free access to food and water throughout the experiment. The rats were dosed via oral gavage with 4 mEq/kg elemental lithium as LISPRO or Li2CO3 dissolved in deionized water or suspended in 1% methylcellulose, respectively. Animals in each treatment group were euthanized at 2, 24, 48, and 72 h (n = 3/time point), and blood was collected by cardiac puncture and carefully perfused with a pressure-controlled pump to maintain microvasculature integrity before removing brain tissue. Blood was centrifuged at 1600g at room temperature for 10 min, and plasma was separated. A 500 \u03bcL aliquot was diluted 10-fold in a 5% TCA and 10% IPA solution, vortexed, and allowed to sit for 10 min in order to precipitate proteins. These aliquots were centrifuged at 3000g for 30 min, and the supernatant was transferred to clean tubes prior to measuring lithium content using atomic absorption spectroscopy (AAS). Brains were rinsed with PBS and weighed, and then an equal volume of concentrated HNO3 was added. The brains were heated in this nitric acid solution for 1 h, allowed to cool to room temperature, and then centrifuged at 3000g for 1 h. The supernatant was removed and diluted 10-fold in 10% IPA prior to measuring lithium content using AAS (Shimadzu AA-6200). Peak height measurements were carried out referring to values obtained for standards of known concentrations. Lithium measurements are plotted as mean \u00b1 SEM.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 26, "type": "text", "classification": ["else"], "content": "<title>Results</title><title>Crystal Structure Description</title><title>Lithium\nSalicylate Proline, LISPRO</title><p>Single crystal X-ray\nstructural analysis reveals that LISPRO contains four lithium cations,\nfour salicylate anions, and four <sc>l</sc>-proline molecules in the\nunit cell. There are two formula units in the asymmetric unit. Each\nlithium cation is linked to adjacent lithium cations by four bridging\ncarboxylate moieties, two from salicylate and two from <sc>l</sc>-proline\n(Li\u2013O distances: 1.916(1), 1.915(1) and 1.875(1), 1.905(1)\n\u00c5). The overall network can be described as square grids and\nis illustrated in Figure A. The hydroxyl group\nof salicylate and protonated nitrogen of <sc>l</sc>-proline are involved\nin intramolecular and intermolecular hydrogen bonds (O\u2013H\u00b7\u00b7\u00b7O<sup>\u2013</sup>: 2.558(1) and 2.641(1); N<sup>+</sup>\u2013H\u00b7\u00b7\u00b7O<sup>\u2013</sup>: 2.751(1), 2.745(1) and 2.874(1) \u00c5) (Table ). The single crystal X-ray diffraction parameters\nof this and the other crystal structures reported herein are tabulated\nin Table .</p>", "clean_text": "Results\n\nCrystal Structure Description\n\nLithium Salicylate Proline, LISPRO\n\nSingle crystal X-ray structural analysis reveals that LISPRO contains four lithium cations, four salicylate anions, and four l-proline molecules in the unit cell. There are two formula units in the asymmetric unit. Each lithium cation is linked to adjacent lithium cations by four bridging carboxylate moieties, two from salicylate and two from l-proline (Li-O distances: 1.916(1), 1.915(1) and 1.875(1), 1.905(1) \u00c5). The overall network can be described as square grids and is illustrated in Figure A. The hydroxyl group of salicylate and protonated nitrogen of l-proline are involved in intramolecular and intermolecular hydrogen bonds (O-H\u22c5\u22c5\u22c5O-: 2.558(1) and 2.641(1); N+-H\u22c5\u22c5\u22c5O-: 2.751(1), 2.745(1) and 2.874(1) \u00c5) (Table ). The single crystal X-ray diffraction parameters of this and the other crystal structures reported herein are tabulated in Table .", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 27, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl2\" orientation=\"portrait\" position=\"float\">\n<label>2</label>\n<caption>\n<title>LISPRO Hydrogen Bonds</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"7\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\">D</oasis:entry>\n<oasis:entry align=\"center\">H</oasis:entry>\n<oasis:entry align=\"center\">A</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(D\u2013H)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(H\u2013A)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(D\u2013A)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">D\u2013H\u2013A/deg</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>N9</oasis:entry>\n<oasis:entry>H9B</oasis:entry>\n<oasis:entry>O3</oasis:entry>\n<oasis:entry>0.91</oasis:entry>\n<oasis:entry>1.84</oasis:entry>\n<oasis:entry>2.750(6)</oasis:entry>\n<oasis:entry>178.4</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>N11</oasis:entry>\n<oasis:entry>H11A</oasis:entry>\n<oasis:entry>O10<xref rid=\"t2fn1\"></xref>\n</oasis:entry>\n<oasis:entry>0.91</oasis:entry>\n<oasis:entry>1.83</oasis:entry>\n<oasis:entry>2.744(6)</oasis:entry>\n<oasis:entry>176.6</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>N11</oasis:entry>\n<oasis:entry>H11B</oasis:entry>\n<oasis:entry>O7</oasis:entry>\n<oasis:entry>0.91</oasis:entry>\n<oasis:entry>2.01</oasis:entry>\n<oasis:entry>2.873(8)</oasis:entry>\n<oasis:entry>158.7</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>O26</oasis:entry>\n<oasis:entry>H26</oasis:entry>\n<oasis:entry>O4</oasis:entry>\n<oasis:entry>0.83</oasis:entry>\n<oasis:entry>1.92</oasis:entry>\n<oasis:entry>2.640(9)</oasis:entry>\n<oasis:entry>144.1</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>O28</oasis:entry>\n<oasis:entry>H28</oasis:entry>\n<oasis:entry>O5</oasis:entry>\n<oasis:entry>0.83</oasis:entry>\n<oasis:entry>1.82</oasis:entry>\n<oasis:entry>2.557(7)</oasis:entry>\n<oasis:entry>146.9</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"t2fn1\">\n<label>a</label>\n<p>1 + <italic toggle=\"yes\">X</italic>, +<italic toggle=\"yes\">Y</italic>, +<italic toggle=\"yes\">Z</italic>.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 28, "type": "text", "classification": ["else"], "content": "<title>Lithium Nicotinate Proline,\nLNAPRO</title><p>The crystal structure\nof LNAPRO reveals that the 1:1 ICC crystallized in space group <italic toggle=\"yes\">P</italic>2<sub>1</sub>2<sub>1</sub>2 and that it contains four lithium\ncations, four nicotinate anions, and four <sc>l</sc>-proline molecules\nin the unit cell. There is one formula unit in the asymmetric unit.\nTwo carboxylate moieties of nicotinate and two carboxylate moieties\nof proline molecules bridge adjacent lithium cations (Li\u2013O\ndistances: 1.897(3), 1.897(3) and 1.920(3), 2.920(3) \u00c5). Undulating\nsquare grid networks are thereby generated as shown in Figure B. The protonated nitrogen atoms of proline form\nhydrogen bonds with carboxylate moieties (N<sup>+</sup>\u2013H\u00b7\u00b7\u00b7O<sup>\u2013</sup>: 2.779(2) and 2.762(2) \u00c5) (Table ).</p>", "clean_text": "Lithium Nicotinate Proline, LNAPRO\n\nThe crystal structure of LNAPRO reveals that the 1:1 ICC crystallized in space group P21212 and that it contains four lithium cations, four nicotinate anions, and four l-proline molecules in the unit cell. There is one formula unit in the asymmetric unit. Two carboxylate moieties of nicotinate and two carboxylate moieties of proline molecules bridge adjacent lithium cations (Li-O distances: 1.897(3), 1.897(3) and 1.920(3), 2.920(3) \u00c5). Undulating square grid networks are thereby generated as shown in Figure B. The protonated nitrogen atoms of proline form hydrogen bonds with carboxylate moieties (N+-H\u22c5\u22c5\u22c5O-: 2.779(2) and 2.762(2) \u00c5) (Table ).", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 29, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl3\" orientation=\"portrait\" position=\"float\">\n<label>3</label>\n<caption>\n<title>LNAPRO Hydrogen Bonds</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"7\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\">D</oasis:entry>\n<oasis:entry align=\"center\">H</oasis:entry>\n<oasis:entry align=\"center\">A</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(D\u2013H)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(H\u2013A)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(D\u2013A)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">D\u2013H\u2013A/deg</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>N5</oasis:entry>\n<oasis:entry>H5A</oasis:entry>\n<oasis:entry>O2</oasis:entry>\n<oasis:entry>0.97(2)</oasis:entry>\n<oasis:entry>1.83(2)</oasis:entry>\n<oasis:entry>2.779(2)</oasis:entry>\n<oasis:entry>163(2)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>N5</oasis:entry>\n<oasis:entry>H5B</oasis:entry>\n<oasis:entry>O1<xref rid=\"t3fn1\"></xref>\n</oasis:entry>\n<oasis:entry>0.95(3)</oasis:entry>\n<oasis:entry>1.81(3)</oasis:entry>\n<oasis:entry>2.762(2)</oasis:entry>\n<oasis:entry>176(2)</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"t3fn1\">\n<label>a</label>\n<p>\u20131/2\n\u2013 <italic toggle=\"yes\">X</italic>, 1/2 + <italic toggle=\"yes\">Y</italic>, \u22121 \u2013 <italic toggle=\"yes\">Z</italic>.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 30, "type": "text", "classification": "error", "content": "<title>LISPRO increases\nPhosphorylation of GSK-3\u03b2 in Rat Hippocampal\nNeural Stem Cells</title><p>Adult rat hippocampal neural stem cells\n(NSC, Millipore) were treated with LISPRO or LIS at 0, 1, and 5 mM\nfor 40 h in a differentiation media and lysates subjected to immunoblotting\nanalysis using an antibody against phosphorylated GSK-3\u03b2 Ser9\n(phosph-GSK-3\u03b2Ser9) or total GSK-3\u03b2. The results from\nthis experiment are shown in Figure . Densitometry\nanalysis was represented by ratio of phosph-GSK-3\u03b2Ser9 to total\nGSK-3\u03b2 band intensity under Western blot. The results of two\nindependent experiments are shown in Figure B as mean \u00b1 SEM. <italic toggle=\"yes\">t</italic>-tests revealed significant\ndifferences in ratio of phosph-GSK-3\u03b2Ser9 to total GSK-3\u03b2\nin 1 and 5 mM of both LISPRO and LIS compared to control (*<italic toggle=\"yes\">p</italic> &lt; 0.05, ***<italic toggle=\"yes\">P</italic> &lt; 0.001). However,\nthere were no significant differences in the ratio of LISPRO and LIS\nat equivalent concentrations, suggesting that ICCs of lithium remain\nbioactive and are bioequivalent to inorganic salts of lithium.</p>", "clean_text": "LISPRO increases Phosphorylation of GSK-3\u03b2 in Rat Hippocampal Neural Stem Cells\n\nAdult rat hippocampal neural stem cells (NSC, Millipore) were treated with LISPRO or LIS at 0, 1, and 5 mM for 40 h in a differentiation media and lysates subjected to immunoblotting analysis using an antibody against phosphorylated GSK-3\u03b2 Ser9 (phosph-GSK-3\u03b2Ser9) or total GSK-3\u03b2. The results from this experiment are shown in Figure . Densitometry analysis was represented by ratio of phosph-GSK-3\u03b2Ser9 to total GSK-3\u03b2 band intensity under Western blot. The results of two independent experiments are shown in Figure B as mean \u00b1 SEM. t-tests revealed significant differences in ratio of phosph-GSK-3\u03b2Ser9 to total GSK-3\u03b2 in 1 and 5 mM of both LISPRO and LIS compared to control (*p < 0.05, ***P < 0.001). However, there were no significant differences in the ratio of LISPRO and LIS at equivalent concentrations, suggesting that ICCs of lithium remain bioactive and are bioequivalent to inorganic salts of lithium.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 31, "type": "figure", "classification": null, "content": "<fig id=\"fig4\" orientation=\"portrait\" position=\"float\">\n<label>4</label>\n<caption>\n<p>LISPRO treatment\nincreases phosphorylation of GSK-3\u03b2 in adult\nrat hippocampal neural stem cells. Adult rat hippocampal neural stem\ncells (NSC, Millipore) were treated with LISPRO or LIS for 40 h in\na differentiated media. (A) Cells were lysed by RIPA buffer with protease\ncocktails and subjected to immunoblotting (WB) analysis using an antibody\nagainst phosphorylated GSK-3\u03b2 Ser9 (phosph-GSK-3\u03b2 Ser9)\nor total GSK-3\u03b2. (B) Densitometry analysis from two independent\nexperiments is represented by ratio of phosph-GSK-3\u03b2 Ser9 to\ntotal GSK-3\u03b2 band intensity under WB. <italic toggle=\"yes\">t</italic>-tests\nrevealed significant differences in ratio of phosph-GSK-3\u03b2 Ser9\nto total GSK-3\u03b2 for 1 and 5 mM of both LISPRO and LIS compared\nto control (*<italic toggle=\"yes\">p</italic> &lt; 0.05, ***<italic toggle=\"yes\">P</italic> &lt;\n0.001). These results are representative of two independent experiments\nwith <italic toggle=\"yes\">n</italic> = 2 for each condition.</p>\n</caption>\n<graphic id=\"gr4\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0002.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 4  LISPRO treatment increases phosphorylation of GSK-3\u03b2 in adult rat hippocampal neural stem cells. Adult rat hippocampal neural stem cells (NSC, Millipore) were treated with LISPRO or LIS for 40 h in a differentiated media. (A) Cells were lysed by RIPA buffer with protease cocktails and subjected to immunoblotting (WB) analysis using an antibody against phosphorylated GSK-3\u03b2 Ser9 (phosph-GSK-3\u03b2 Ser9) or total GSK-3\u03b2. (B) Densitometry analysis from two independent experiments is represented by ratio of phosph-GSK-3\u03b2 Ser9 to total GSK-3\u03b2 band intensity under WB. t-tests revealed significant differences in ratio of phosph-GSK-3\u03b2 Ser9 to total GSK-3\u03b2 for 1 and 5 mM of both LISPRO and LIS compared to control (*p < 0.05, ***P < 0.001). These results are representative of two independent experiments with n = 2 for each condition.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 32, "type": "text", "classification": ["else"], "content": "<title>LISPRO Increases BDNF Production <italic toggle=\"yes\">in Vitro</italic>\n</title><p>Mouse neuroblastoma (N2a) cells were treated with LIS and LISPRO\nat 5 and 25 mM in DMEM supplemented with 5% FBS for 48 h. BDNF quantification\nwas determined via ELISA kit. We found that both LIS and LISPRO produced\ndose dependent increases in BDNF (Figure ).\nThis bioactivity of lithium has been previously reported for conventional\nlithium salts. This provides further evidence\nthat the lithium remains bioactive despite being in the ICC form,\nLISPRO.</p>", "clean_text": "LISPRO Increases BDNF Production in Vitro \n\nMouse neuroblastoma (N2a) cells were treated with LIS and LISPRO at 5 and 25 mM in DMEM supplemented with 5% FBS for 48 h. BDNF quantification was determined via ELISA kit. We found that both LIS and LISPRO produced dose dependent increases in BDNF (Figure ). This bioactivity of lithium has been previously reported for conventional lithium salts. This provides further evidence that the lithium remains bioactive despite being in the ICC form, LISPRO.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 33, "type": "figure", "classification": null, "content": "<fig id=\"fig5\" orientation=\"portrait\" position=\"float\">\n<label>5</label>\n<caption>\n<p>LISPRO treatment induces BDNF production by neurons. Neuroblastoma\ncells were treated with LIS and LISPRO for 48 h. BDNF was quantified\nin the media by ELISA and normalized to total protein in the cell\nlysate by BCA. <italic toggle=\"yes\">t</italic>-tests revealed significant differences\nat 1 and 10 mM for LISPRO compared to the no treatment control (*<italic toggle=\"yes\">p</italic> &lt; 0.05) and only at 10 mM for LIS (**<italic toggle=\"yes\">p</italic> &lt; 0.01). There were no statistically significant differences\nbetween LIS and LISPRO at either concentration (<italic toggle=\"yes\">p</italic> &gt; 0.05).</p>\n</caption>\n<graphic id=\"gr5\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0003.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 5  LISPRO treatment induces BDNF production by neurons. Neuroblastoma cells were treated with LIS and LISPRO for 48 h. BDNF was quantified in the media by ELISA and normalized to total protein in the cell lysate by BCA. t-tests revealed significant differences at 1 and 10 mM for LISPRO compared to the no treatment control (*p < 0.05) and only at 10 mM for LIS (**p < 0.01). There were no statistically significant differences between LIS and LISPRO at either concentration (p > 0.05).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 34, "type": "text", "classification": "error", "content": "<title>LISPRO Attenuates NO Production\nin LPS-Activated Microglia</title><p>BV2 microglia cells were treated\nwith LIS and LISPRO at 12.5 and\n25 mM in DMEM for 30 min prior to activation of microglia by 100 ng/mL\nLPS. NO was measured in the media 6 h later using a Griess Reagent\nsystem. Results are shown in Figure . We found\nthat LPS increased NO production by BV2 microglia. Further, lithium\ntreatment (both as LIS and LISPRO) attenuated this proinflammatory\nresponse. At 25 mM, both lithium forms completely inhibited NO production.\nAt 12.5 mM, we found LISPRO to be more effective than LIS at attenuating\nNO production in these LPS-activated microglia. This supports the\nbioactivity of LISPRO and suggests that, in some instances, it may\nbe advantageous to the parent salt form, LIS.</p>", "clean_text": "LISPRO Attenuates NO Production in LPS-Activated Microglia\n\nBV2 microglia cells were treated with LIS and LISPRO at 12.5 and 25 mM in DMEM for 30 min prior to activation of microglia by 100 ng/mL LPS. NO was measured in the media 6 h later using a Griess Reagent system. Results are shown in Figure . We found that LPS increased NO production by BV2 microglia. Further, lithium treatment (both as LIS and LISPRO) attenuated this proinflammatory response. At 25 mM, both lithium forms completely inhibited NO production. At 12.5 mM, we found LISPRO to be more effective than LIS at attenuating NO production in these LPS-activated microglia. This supports the bioactivity of LISPRO and suggests that, in some instances, it may be advantageous to the parent salt form, LIS.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 35, "type": "figure", "classification": null, "content": "<fig id=\"fig6\" orientation=\"portrait\" position=\"float\">\n<label>6</label>\n<caption>\n<p>LISPRO treatment abolishes\nNO production in LPS-activated microglia.\nBV2 microglia were pretreated with LIS and LISPRO at 25 and 12.5 mM\nfor 1 h prior to being activated by the addition of 100 ng/mL LPS.\nEighteen hours later, media was collected and NO was measured. The\nno treatment, no LPS control group produced very low (basal) levels\nof NO. The no treatment with LPS control group produced the highest\nlevels of NO. The lithium treatments abolished NO production at 25\nmM and reduced it at 12.5 mM with LISPRO being advantageous at this\nconcentration. Statistical significance from the no treatment with\nLPS control was assessed by <italic toggle=\"yes\">t</italic>-tests (*<italic toggle=\"yes\">p</italic> &lt; 0.05, **<italic toggle=\"yes\">p</italic> &lt; 0.01, ***<italic toggle=\"yes\">p</italic> &lt; 0.001).</p>\n</caption>\n<graphic id=\"gr6\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0004.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 6  LISPRO treatment abolishes NO production in LPS-activated microglia. BV2 microglia were pretreated with LIS and LISPRO at 25 and 12.5 mM for 1 h prior to being activated by the addition of 100 ng/mL LPS. Eighteen hours later, media was collected and NO was measured. The no treatment, no LPS control group produced very low (basal) levels of NO. The no treatment with LPS control group produced the highest levels of NO. The lithium treatments abolished NO production at 25 mM and reduced it at 12.5 mM with LISPRO being advantageous at this concentration. Statistical significance from the no treatment with LPS control was assessed by t-tests (*p < 0.05, **p < 0.01, ***p < 0.001).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 36, "type": "text", "classification": ["else"], "content": "<title>LISPRO Induces Neuronal\nDifferentiation of Stem Cells</title><p>Lithium has been shown to promote\nneuronal differentiation of hippocampal\nprogenitor cells. To test whether LISPRO\npossessed this bioactivity, we treated adult rat hippocampal neural\nstem cells with lithium as LIS and LISPRO at 3 mM for 5 days. Immunocytochemistry\nstudies indicated that, compared to the no treatment control group\n(Figure A), both LIS (Figure B) and LISPRO (Figure C) did indeed\npromote differentiation of the progenitor cells into neurons over\nthe course of the experiment.</p>", "clean_text": "LISPRO Induces Neuronal Differentiation of Stem Cells\n\nLithium has been shown to promote neuronal differentiation of hippocampal progenitor cells. To test whether LISPRO possessed this bioactivity, we treated adult rat hippocampal neural stem cells with lithium as LIS and LISPRO at 3 mM for 5 days. Immunocytochemistry studies indicated that, compared to the no treatment control group (Figure A), both LIS (Figure B) and LISPRO (Figure C) did indeed promote differentiation of the progenitor cells into neurons over the course of the experiment.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 37, "type": "figure", "classification": null, "content": "<fig id=\"fig7\" orientation=\"portrait\" position=\"float\">\n<label>7</label>\n<caption>\n<p>LISPRO induces neuronal differentiation of stem\ncells. Adult rat\nhippocampal neural stem cells were cultured with neurobasal media\nonly (A), neurobasal media with 3 mM LIS (B), and neurobasal media\nwith 3 mM LISPRO (C). Blue DAPI staining indicates nuclei, red GFAP\nstaining indicates astrocytes, and green Tuj1 indicates neurons.</p>\n</caption>\n<graphic id=\"gr7\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0005.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 7  LISPRO induces neuronal differentiation of stem cells. Adult rat hippocampal neural stem cells were cultured with neurobasal media only (A), neurobasal media with 3 mM LIS (B), and neurobasal media with 3 mM LISPRO (C). Blue DAPI staining indicates nuclei, red GFAP staining indicates astrocytes, and green Tuj1 indicates neurons.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 38, "type": "text", "classification": "error", "content": "<title>LISPRO Pharmacokinetics\nin Rats</title><p>Male Sprague\u2013Dawley\nrats weighing 200\u2013250 g were dosed via oral gavage with 4 mEq/kg\nelemental lithium as the ICC LISPRO dissolved in deionized water or\nlithium carbonate (Li<sub>2</sub>CO<sub>3</sub>) suspended in 1% methylcellulose.\nAnimals in each treatment group were euthanized at 2, 24, 48, and\n72 h (<italic toggle=\"yes\">n</italic> = 3/time point), and blood and brain were\ncollected. Lithium was quantified using atomic absorption spectroscopy\n(AAS). Lithium measurements are plotted as mean \u00b1 SEM in Figure . The plasma pharmacokinetics of Li<sub>2</sub>CO<sub>3</sub> produced a sharp peak and rapid elimination with nearly undetectable\nlevels at 48 h (Figure A). This produced a\nconcomitant spike in brain lithium levels at 24 h (Figure B). LISPRO produced elevated lithium plasma levels\nat the earliest time point (2 h) (Figure C).\nThe plasma lithium levels peaked at 24 h and remained elevated at\n48 h before becoming almost undetectable at 72 h. LISPRO produced\nsteady brain levels of lithium at 24 and 48 h (Figure D). The compilation of LISPRO versus Li<sub>2</sub>CO<sub>3</sub> plasma (Figure E) and brain (Figure F) pharmacokinetics reveals some distinct differences\nbetween the ICC and salt forms. Although LISPRO produced very steady\nlithium plasma and brain levels out to 48 h, it was at the cost of\nbioavailability, which was clearly reduced compared to Li<sub>2</sub>CO<sub>3</sub> in both the plasma and brain compartments. Relative\nplasma and brain bioavailability of LISPRO was 39% and 56%, respectively.</p>", "clean_text": "LISPRO Pharmacokinetics in Rats\n\nMale Sprague-Dawley rats weighing 200-250 g were dosed via oral gavage with 4 mEq/kg elemental lithium as the ICC LISPRO dissolved in deionized water or lithium carbonate (Li2CO3) suspended in 1% methylcellulose. Animals in each treatment group were euthanized at 2, 24, 48, and 72 h (n = 3/time point), and blood and brain were collected. Lithium was quantified using atomic absorption spectroscopy (AAS). Lithium measurements are plotted as mean \u00b1 SEM in Figure . The plasma pharmacokinetics of Li2CO3 produced a sharp peak and rapid elimination with nearly undetectable levels at 48 h (Figure A). This produced a concomitant spike in brain lithium levels at 24 h (Figure B). LISPRO produced elevated lithium plasma levels at the earliest time point (2 h) (Figure C). The plasma lithium levels peaked at 24 h and remained elevated at 48 h before becoming almost undetectable at 72 h. LISPRO produced steady brain levels of lithium at 24 and 48 h (Figure D). The compilation of LISPRO versus Li2CO3 plasma (Figure E) and brain (Figure F) pharmacokinetics reveals some distinct differences between the ICC and salt forms. Although LISPRO produced very steady lithium plasma and brain levels out to 48 h, it was at the cost of bioavailability, which was clearly reduced compared to Li2CO3 in both the plasma and brain compartments. Relative plasma and brain bioavailability of LISPRO was 39% and 56%, respectively.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 39, "type": "figure", "classification": null, "content": "<fig id=\"fig8\" orientation=\"portrait\" position=\"float\">\n<label>8</label>\n<caption>\n<p>\n<italic toggle=\"yes\">In vivo</italic> plasma and brain pharmacokinetics of LISPRO\nand Li<sub>2</sub>CO<sub>3</sub>. Male rats (<italic toggle=\"yes\">n</italic> =\n3 per formulation per time point) were dosed with 4 mEq/kg of lithium\nvia oral gavage as LISPRO or Li<sub>2</sub>CO<sub>3</sub>. Plasma\nand brain lithium levels were determined at 2, 24, 48, and 72 h by\natomic absorption spectrometry. (A) Li<sub>2</sub>CO<sub>3</sub> plasma\nlithium concentration versus time (mean \u00b1 SEM). (B) Li<sub>2</sub>CO<sub>3</sub> brain lithium per gram of wet weight versus time (mean\n\u00b1 SEM). (C) LISPRO plasma lithium concentration versus time (mean\n\u00b1 SEM). (D) LISPRO brain lithium per gram of wet weight versus\ntime (mean \u00b1 SEM). (E) Compilation plasma lithium concentration\nversus time (mean \u00b1 SEM). (F) Compilation brain lithium concentration\nversus time (mean \u00b1 SEM).</p>\n</caption>\n<graphic id=\"gr8\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0006.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 8   In vivo plasma and brain pharmacokinetics of LISPRO and Li2CO3. Male rats (n = 3 per formulation per time point) were dosed with 4 mEq/kg of lithium via oral gavage as LISPRO or Li2CO3. Plasma and brain lithium levels were determined at 2, 24, 48, and 72 h by atomic absorption spectrometry. (A) Li2CO3 plasma lithium concentration versus time (mean \u00b1 SEM). (B) Li2CO3 brain lithium per gram of wet weight versus time (mean \u00b1 SEM). (C) LISPRO plasma lithium concentration versus time (mean \u00b1 SEM). (D) LISPRO brain lithium per gram of wet weight versus time (mean \u00b1 SEM). (E) Compilation plasma lithium concentration versus time (mean \u00b1 SEM). (F) Compilation brain lithium concentration versus time (mean \u00b1 SEM).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 40, "type": "text", "classification": ["else"], "content": "<title>Discussion</title><p>In regard to the therapeutic activity of\nvarious lithium salts\nfor the treatment of bipolar disorder, equivalence is often assumed\nbecause the lithium cation is regarded as the API. Our bioactivity\nassessments of a new lithium ICC compared to the parent lithium salt\nsupports this assumption only for the clinically relevant end points\nthat we evaluated <italic toggle=\"yes\">in vitro</italic>. Importantly, because\nthe molecular ideology of bipolar disorder is not fully understood,\nwe cannot conclude that various forms of lithium will be equally effective\nat treating bipolar disorder <italic toggle=\"yes\">in vivo</italic>. However, in\nthis regard, we note that certain lithium salts alone might offer\nsignificant benefits from an efficacy and/or toxicity standpoint.</p>", "clean_text": "Discussion\n\nIn regard to the therapeutic activity of various lithium salts for the treatment of bipolar disorder, equivalence is often assumed because the lithium cation is regarded as the API. Our bioactivity assessments of a new lithium ICC compared to the parent lithium salt supports this assumption only for the clinically relevant end points that we evaluated in vitro. Importantly, because the molecular ideology of bipolar disorder is not fully understood, we cannot conclude that various forms of lithium will be equally effective at treating bipolar disorder in vivo. However, in this regard, we note that certain lithium salts alone might offer significant benefits from an efficacy and/or toxicity standpoint.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 41, "type": "text", "classification": ["else"], "content": "<p>To our knowledge, there have been no side-by-side clinical evaluations\nof the therapeutic efficacy of the lithium salts that we utilized\nhere. However, empirical evidence suggests that some of the anions\nmight be therapeutically synergistic with lithium for the treatment\nof bipolar disorder. For example, a recent pharmacoepidemiological\nstudy suggests that acetylsalicylic acid (aspirin) might be beneficial\nas an adjunct treatment with lithium salts for the treatment of bipolar\ndisorder. The anion in LISPRO, salicylic\nacid, is the primary bioactive metabolite of aspirin. Stolk et al.\nreported that low-dose aspirin produced significant reduction in the\nrelative risk of clinical deterioration in subjects on lithium and\nthat this was not the case with other NSAIDs and glucocorticoids. The authors hypothesize that this is due to\nsynergistic anti-inflammatory actions of lithium and acetylsalicylic\nacid by increasing the brain concentrations of 17-OH-DHA, an anti-inflammatory\nbrain DHA metabolite. This hypothesis is supported by previous studies\nthat demonstrated neuroinflammation in BD, that aspirin increases 17-OH-DHA, and\nthat lithium reduces neuroinflammation. Lithium nicotinate has\nbeen used in Russia for the treatment of alcoholism and stress. This lithium salt is distinguished by low toxicity and good tolerance. Collectively, these findings suggest that lithium\nsalicylate and lithium nicotinate might be advantageous to current\nFDA-approved lithium salts from efficacy and toxicity standpoints,\nrespectively. As such, they are ideal as building blocks for the next\ngeneration of lithium therapeutics. Conversely, other lithium salts\nshould probably be avoided for pharmaceutical applications. In two\nrecent communications, Wouters et al. and Braga et al. reported new\nICCs of lithium chloride and lithium bromide with racetams. Although racetams generally possess good toxicity profiles and might\nprove to act synergistically with lithium, bromide salts have been\nknown to cause serious side effects that were coined bromism. This illustrates the importance of considering the safety of all\ncomponents during crystal engineering studies that involve pharmaceutical\nmaterials. All components of LISPRO and LNAPRO are considered pharmaceutically\nacceptable.</p>", "clean_text": "To our knowledge, there have been no side-by-side clinical evaluations of the therapeutic efficacy of the lithium salts that we utilized here. However, empirical evidence suggests that some of the anions might be therapeutically synergistic with lithium for the treatment of bipolar disorder. For example, a recent pharmacoepidemiological study suggests that acetylsalicylic acid (aspirin) might be beneficial as an adjunct treatment with lithium salts for the treatment of bipolar disorder. The anion in LISPRO, salicylic acid, is the primary bioactive metabolite of aspirin. Stolk et al. reported that low-dose aspirin produced significant reduction in the relative risk of clinical deterioration in subjects on lithium and that this was not the case with other NSAIDs and glucocorticoids. The authors hypothesize that this is due to synergistic anti-inflammatory actions of lithium and acetylsalicylic acid by increasing the brain concentrations of 17-OH-DHA, an anti-inflammatory brain DHA metabolite. This hypothesis is supported by previous studies that demonstrated neuroinflammation in BD, that aspirin increases 17-OH-DHA, and that lithium reduces neuroinflammation. Lithium nicotinate has been used in Russia for the treatment of alcoholism and stress. This lithium salt is distinguished by low toxicity and good tolerance. Collectively, these findings suggest that lithium salicylate and lithium nicotinate might be advantageous to current FDA-approved lithium salts from efficacy and toxicity standpoints, respectively. As such, they are ideal as building blocks for the next generation of lithium therapeutics. Conversely, other lithium salts should probably be avoided for pharmaceutical applications. In two recent communications, Wouters et al. and Braga et al. reported new ICCs of lithium chloride and lithium bromide with racetams. Although racetams generally possess good toxicity profiles and might prove to act synergistically with lithium, bromide salts have been known to cause serious side effects that were coined bromism. This illustrates the importance of considering the safety of all components during crystal engineering studies that involve pharmaceutical materials. All components of LISPRO and LNAPRO are considered pharmaceutically acceptable.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 42, "type": "text", "classification": ["else"], "content": "<p>Development of multicomponent salt forms as APIs\nfor the treatment\nof bipolar disorder would require high monetary investment and development\nof such drug products would therefore have to be enabled through exclusive\nintellectual property protection. Cocrystals of existing APIs have\nbeen deemed nonobvious and, therefore, patentable. Moreover, they are known to modify the physicochemical\nproperties and pharmacokinetics of an API. In our experiments, we\nsynthesized and characterized novel ICCs of lithium salicylate and\nlithium nicotinate with the amino acid proline. LISPRO was selected\nfor efficacy and pharmacokinetic evaluations due to the likelihood\nfor additive or possibly even synergistic effects in treating neuropsychiatric\ndiseases due to the biologically noninert anion, salicylic acid.</p>", "clean_text": "Development of multicomponent salt forms as APIs for the treatment of bipolar disorder would require high monetary investment and development of such drug products would therefore have to be enabled through exclusive intellectual property protection. Cocrystals of existing APIs have been deemed nonobvious and, therefore, patentable. Moreover, they are known to modify the physicochemical properties and pharmacokinetics of an API. In our experiments, we synthesized and characterized novel ICCs of lithium salicylate and lithium nicotinate with the amino acid proline. LISPRO was selected for efficacy and pharmacokinetic evaluations due to the likelihood for additive or possibly even synergistic effects in treating neuropsychiatric diseases due to the biologically noninert anion, salicylic acid.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 43, "type": "text", "classification": "error", "content": "<p>To our knowledge, this represents the first biological assessment\nof what is likely to become a very important class of pharmaceutical\nmaterials (ICCs). Our findings suggest that this change in speciation\ndid not negatively affect the <italic toggle=\"yes\">in vitro</italic> bioactivity\nof lithium at established targets for the treatment of neuropsychiatric\ndisorders relative to the corresponding parent lithium salt. Furthermore,\nthis is the first report of the pharmacokinetics of a cocrystal of\na suspected BCS class I API as defined by Amidon et al. Compared to an FDA-approved lithium salt, lithium\ncarbonate (Li<sub>2</sub>CO<sub>3</sub>)<sub>,</sub> in addition to\nbeing more efficacious by exploiting potential synergies, LISPRO may\nalso offer a better safety profile due to unexpected pharmacokinetic\nchanges. We found that a 4 mEq/kg dose of LISPRO to rats provided\nconsistently elevated levels of lithium in the plasma and brain out\nto 48 h. Conversely, Li<sub>2</sub>CO<sub>3</sub> was almost undetectable\nat 48 h in the plasma and produced a large spike in the plasma and\nbrain at 24 h post dose. This type of pharmacokinetic profile can\ncontribute to the toxicity of lithium given its narrow therapeutic\nwindow. Indeed, Lippman and Evans suggested that an ideal lithium\npreparation would attenuate high blood level peaks and exhibit gradually\ndeclining blood concentrations. This\nhas been the driving logic behind the development and evaluation of\nmany controlled release formulations. Recently, Emami et al.\nevaluated the pharmacokinetics of a proprietary sustained-release\nLi<sub>2</sub>CO<sub>3</sub> formulation compared to Eskalith CR,\nthe FDA approved controlled-release Li<sub>2</sub>CO<sub>3</sub> formulation,\nand conventional Li<sub>2</sub>CO<sub>3</sub> in man. They found that the plasma spike produced by conventional\nlithium carbonate was greatly reduced in their proprietary formulation\nand Eskalith CR and conclude that this could be used to reduce the\nfrequency of dosing and improve patient compliance. The pharmacokinetics\nexhibited by our ICC of lithium salicylate, LISPRO, is very similar\nto those in controlled release formulations. This apparent pharmacokinetic\nadvantage of LISPRO compared to conventional lithium carbonate was\nunexpected. Although serendipitous in nature, this finding could be\nkey in creating the next generation of lithium therapeutics. If these\npharmacokinetic changes can be used to modify the dosing regimen for\nlithium therapy, this could improve patient compliance and reduce\ntoxicity. Future studies are required to evaluate potential toxicity\nand efficacy advantages <italic toggle=\"yes\">in vivo</italic> during maintenance\nlithium therapy conditions.</p>", "clean_text": "To our knowledge, this represents the first biological assessment of what is likely to become a very important class of pharmaceutical materials (ICCs). Our findings suggest that this change in speciation did not negatively affect the in vitro bioactivity of lithium at established targets for the treatment of neuropsychiatric disorders relative to the corresponding parent lithium salt. Furthermore, this is the first report of the pharmacokinetics of a cocrystal of a suspected BCS class I API as defined by Amidon et al. Compared to an FDA-approved lithium salt, lithium carbonate (Li2CO3), in addition to being more efficacious by exploiting potential synergies, LISPRO may also offer a better safety profile due to unexpected pharmacokinetic changes. We found that a 4 mEq/kg dose of LISPRO to rats provided consistently elevated levels of lithium in the plasma and brain out to 48 h. Conversely, Li2CO3 was almost undetectable at 48 h in the plasma and produced a large spike in the plasma and brain at 24 h post dose. This type of pharmacokinetic profile can contribute to the toxicity of lithium given its narrow therapeutic window. Indeed, Lippman and Evans suggested that an ideal lithium preparation would attenuate high blood level peaks and exhibit gradually declining blood concentrations. This has been the driving logic behind the development and evaluation of many controlled release formulations. Recently, Emami et al. evaluated the pharmacokinetics of a proprietary sustained-release Li2CO3 formulation compared to Eskalith CR, the FDA approved controlled-release Li2CO3 formulation, and conventional Li2CO3 in man. They found that the plasma spike produced by conventional lithium carbonate was greatly reduced in their proprietary formulation and Eskalith CR and conclude that this could be used to reduce the frequency of dosing and improve patient compliance. The pharmacokinetics exhibited by our ICC of lithium salicylate, LISPRO, is very similar to those in controlled release formulations. This apparent pharmacokinetic advantage of LISPRO compared to conventional lithium carbonate was unexpected. Although serendipitous in nature, this finding could be key in creating the next generation of lithium therapeutics. If these pharmacokinetic changes can be used to modify the dosing regimen for lithium therapy, this could improve patient compliance and reduce toxicity. Future studies are required to evaluate potential toxicity and efficacy advantages in vivo during maintenance lithium therapy conditions.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 44, "type": "text", "classification": ["else"], "content": "<p>Since we have attained a more attractive <italic toggle=\"yes\">in vivo</italic> pharmacokinetic profile and equivalent <italic toggle=\"yes\">in\nvitro</italic> bioactivity at key therapeutic points, it would be\nquite significant\nif we could alleviate side effects <italic toggle=\"yes\">in vivo</italic> or exploit\nsynergistic activities with these or other lithium ICCs. Specifically,\nfuture studies are required to assess safety and efficacy advantages\nof lithium ICCs <italic toggle=\"yes\">in vivo</italic>. Indeed, these findings represent\nan important initial step in the crystal engineering enabled development\nof the next generation of lithium therapeutics.</p>", "clean_text": "Since we have attained a more attractive in vivo pharmacokinetic profile and equivalent in vitro bioactivity at key therapeutic points, it would be quite significant if we could alleviate side effects in vivo or exploit synergistic activities with these or other lithium ICCs. Specifically, future studies are required to assess safety and efficacy advantages of lithium ICCs in vivo. Indeed, these findings represent an important initial step in the crystal engineering enabled development of the next generation of lithium therapeutics.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 45, "type": "text", "classification": ["else"], "content": "<p>Additional data as described\nin the text. This material is available free of charge via the Internet\nat <uri xlink:href=\"http://pubs.acs.org\" xlink:type=\"simple\">http://pubs.acs.org</uri>.</p><p>AS synthesized\nand characterized LISPRO, designed and conducted <italic toggle=\"yes\">in vivo</italic> experiments, and wrote the paper. NKD synthesized and characterized\nLNAPRO. LW solved the crystal structures. AS, JJ, and SK carried out <italic toggle=\"yes\">in vitro</italic> experiments. JT, BG, and JE provided help and advice\nwith <italic toggle=\"yes\">in vitro</italic> experiments. RS and MZ managed the\nproject and are joint senior authors. All authors contributed to final\nedits.</p>", "clean_text": "Additional data as described in the text. This material is available free of charge via the Internet at http://pubs.acs.org.\n\nAS synthesized and characterized LISPRO, designed and conducted in vivo experiments, and wrote the paper. NKD synthesized and characterized LNAPRO. LW solved the crystal structures. AS, JJ, and SK carried out in vitro experiments. JT, BG, and JE provided help and advice with in vitro experiments. RS and MZ managed the project and are joint senior authors. All authors contributed to final edits.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 46, "type": "text", "classification": ["else"], "content": "<p>The authors\ndeclare the following competing financial interest(s): AS, ND, RS,\nand MZ are inventors on patent applications pertaining to these technologies.</p><title>Abbreviations List</title><p>active pharmaceutical ingredient</p><p>powder X-ray diffraction</p><p>differential scanning\ncalorimeter</p><p>infrared spectroscopy</p><p>thermogravimetric analysis</p><p>ionic cocrystal</p><title>References</title>", "clean_text": "The authors declare the following competing financial interest(s): AS, ND, RS, and MZ are inventors on patent applications pertaining to these technologies.\n\nAbbreviations List\n\nactive pharmaceutical ingredient\n\npowder X-ray diffraction\n\ndifferential scanning calorimeter\n\ninfrared spectroscopy\n\nthermogravimetric analysis\n\nionic cocrystal\n\nReferences", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}], "cln_elements": [{"idx": "10, 11", "type": "text", "classification": "synthesis condition", "content": "<title>Lithium Cocrystal Syntheses</title><title>LISPRO</title><p>Lithium salicylate (\u226598%\npure, anhydrous,\nused as received from Sigma Aldrich, 1 mmol) and <sc>l</sc>-proline\n(\u226599% pure, used as received from Sigma Aldrich, 1 mmol) were\ndissolved in 2.0 mL of hot deionized water. The resulting solution\nwas maintained on a hot plate (75\u201390 \u00b0C) to allow slow\nevaporation of solvent until crystals had formed. Colorless crystals\nof LISPRO were collected.</p><title>LNAPRO</title><p>Lithium hydroxide (\u226598%\npure, anhydrous,\nused as received from Sigma Aldrich, 1 mmol), nicotinic acid (\u226598%\npure, anhydrous, used as received from Sigma Aldrich, 1 mmol), and <sc>l</sc>-proline (\u226599% pure, used as received from Sigma Aldrich,\n2 mmol) were dissolved in 3.0 mL of deionized water and left to stand\non a hot plate until block shape colorless crystals had emerged from\nsolution.\n</p>", "clean_text": "Lithium Cocrystal Syntheses\n\nLISPRO\n\nLithium salicylate (\u226598% pure, anhydrous, used as received from Sigma Aldrich, 1 mmol) and l-proline (\u226599% pure, used as received from Sigma Aldrich, 1 mmol) were dissolved in 2.0 mL of hot deionized water. The resulting solution was maintained on a hot plate (75-90 \u00b0C) to allow slow evaporation of solvent until crystals had formed. Colorless crystals of LISPRO were collected.\n\nLNAPRO\n\nLithium hydroxide (\u226598% pure, anhydrous, used as received from Sigma Aldrich, 1 mmol), nicotinic acid (\u226598% pure, anhydrous, used as received from Sigma Aldrich, 1 mmol), and l-proline (\u226599% pure, used as received from Sigma Aldrich, 2 mmol) were dissolved in 3.0 mL of deionized water and left to stand on a hot plate until block shape colorless crystals had emerged from solution. ", "data": [[{"meta": {"name": "LISPRO", "symbol": "", "chemical formula": ""}, "processes": [{"synthesis method": "chemical synthesis", "precursor": [{"name": "Lithium salicylate", "amount": "1", "unit": "mmol"}, {"name": "l-proline", "amount": "1", "unit": "mmol"}], "solution": [{"name": "hot deionized water", "amount": "2.0", "unit": "mL"}], "pressure": "", "temperature": "75-90 \u00b0C", "time": ""}], "yield": ""}, {"meta": {"name": "LNAPRO", "symbol": "", "chemical formula": ""}, "processes": [{"synthesis method": "chemical synthesis", "precursor": [{"name": "Lithium hydroxide", "amount": "1", "unit": "mmol"}, {"name": "nicotinic acid", "amount": "1", "unit": "mmol"}, {"name": "l-proline", "amount": "2", "unit": "mmol"}], "solution": [{"name": "deionized water", "amount": "3.0", "unit": "mL"}], "pressure": "", "temperature": "", "time": ""}], "yield": ""}]], "include_properties": ["chemical_synthesis"], "intermediate_step": {"text-synthesis-type": "['chemical_synthesis']", "text-synthesis-struct": "```JSON\n[{\"meta\":{\"name\":\"LISPRO\", \"symbol\":\"\", \"chemical formula\":\"\"}, \"processes\":[{\"synthesis method\": \"chemical synthesis\", \"precursor\":[{\"name\":\"Lithium salicylate\", \"amount\":\"1\", \"unit\":\"mmol\"}, {\"name\":\"l-proline\", \"amount\":\"1\", \"unit\":\"mmol\"}], \"solution\":[{\"name\":\"hot deionized water\", \"amount\":\"2.0\", \"unit\":\"mL\"}], \"pressure\": \"\", \"temperature\":\"75-90 \u00b0C\", \"time\":\"\"}], \"yield\": \"\"}, {\"meta\":{\"name\":\"LNAPRO\", \"symbol\":\"\", \"chemical formula\":\"\"}, \"processes\":[{\"synthesis method\": \"chemical synthesis\", \"precursor\":[{\"name\":\"Lithium hydroxide\", \"amount\":\"1\", \"unit\":\"mmol\"}, {\"name\":\"nicotinic acid\", \"amount\":\"1\", \"unit\":\"mmol\"}, {\"name\":\"l-proline\", \"amount\":\"2\", \"unit\":\"mmol\"}], \"solution\":[{\"name\":\"deionized water\", \"amount\":\"3.0\", \"unit\":\"mL\"}], \"pressure\": \"\", \"temperature\": \"\", \"time\":\"\"}], \"yield\": \"\"}]\n```"}}, {"idx": 16, "type": "table", "classification": ["Crystal"], "content": "<table-wrap id=\"tbl1\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Crystallographic Data and Structure\nRefinement Parameters</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"3\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col3\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\">LISPRO</oasis:entry>\n<oasis:entry align=\"center\">LNAPRO</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>formula</oasis:entry>\n<oasis:entry>C<sub>12</sub>H<sub>14</sub>LiNO<sub>5</sub>\n</oasis:entry>\n<oasis:entry>C<sub>11</sub>H<sub>13</sub>LiN<sub>2</sub>O<sub>4</sub>\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>MW</oasis:entry>\n<oasis:entry>259.18</oasis:entry>\n<oasis:entry>244.17</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>crystal system</oasis:entry>\n<oasis:entry>monoclinic</oasis:entry>\n<oasis:entry>orthorhombic</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>space group</oasis:entry>\n<oasis:entry>\n<italic toggle=\"yes\">P</italic>2<sub>1</sub>\n</oasis:entry>\n<oasis:entry>\n<italic toggle=\"yes\">P</italic>2<sub>1</sub>2<sub>1</sub>2</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">a</italic> (\u00c5)</oasis:entry>\n<oasis:entry>10.3601(19)</oasis:entry>\n<oasis:entry>10.2156(2)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">b</italic> (\u00c5)</oasis:entry>\n<oasis:entry>10.1556(16)</oasis:entry>\n<oasis:entry>10.4646(3)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">c</italic> (\u00c5)</oasis:entry>\n<oasis:entry>12.173(3)</oasis:entry>\n<oasis:entry>11.3811(3)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b1 (deg)</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b2 (deg)</oasis:entry>\n<oasis:entry>93.415(11)</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b3 (deg)</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n<oasis:entry>90.00</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">V</italic> (\u00c5<sup>3</sup>)</oasis:entry>\n<oasis:entry>1278.5(4)</oasis:entry>\n<oasis:entry>1216.66(5)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">D</italic>\n<sub>c</sub> (mg\u00a0m<sup>\u20113</sup>)</oasis:entry>\n<oasis:entry>1.347</oasis:entry>\n<oasis:entry>1.333</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">Z</italic>\n</oasis:entry>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>4</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2\u03b8 range</oasis:entry>\n<oasis:entry>7.28\u2013131.94\u00b0</oasis:entry>\n<oasis:entry>7.76\u2013131.9\u00b0</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">N</italic>\n<sub>ref</sub>/<italic toggle=\"yes\">N</italic>\n<sub>para</sub>\n</oasis:entry>\n<oasis:entry>6896/352</oasis:entry>\n<oasis:entry>2116/183</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">T</italic>  (K)</oasis:entry>\n<oasis:entry>228(2)</oasis:entry>\n<oasis:entry>228(2)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>R<sub>1</sub> [<italic toggle=\"yes\">I</italic>\u00a0&gt;\u00a02\u03c3(<italic toggle=\"yes\">I</italic>)]</oasis:entry>\n<oasis:entry>0.0394</oasis:entry>\n<oasis:entry>0.0394</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic toggle=\"yes\">w</italic>R<sub>2</sub>\n</oasis:entry>\n<oasis:entry>0.0935</oasis:entry>\n<oasis:entry>0.0935</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>GOF</oasis:entry>\n<oasis:entry>0.988</oasis:entry>\n<oasis:entry>0.988</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>abs coef.</oasis:entry>\n<oasis:entry>0.872</oasis:entry>\n<oasis:entry>0.843</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "Table 1. Crystallographic Data and Structure Refinement Parameters\n\n|                  | LISPRO       | LNAPRO       |\n|------------------|--------------|--------------|\n| formula          | C<sub>12</sub>H<sub>14</sub>LiNO<sub>5</sub> | C<sub>11</sub>H<sub>13</sub>LiN<sub>2</sub>O<sub>4</sub> |\n| MW               | 259.18       | 244.17       |\n| crystal system   | monoclinic   | orthorhombic |\n| space group      | *P*2<sub>1</sub> | *P*2<sub>1</sub>2<sub>1</sub>2 |\n| *a* (\u00c5)           | 10.3601(19)  | 10.2156(2)   |\n| *b* (\u00c5)           | 10.1556(16)  | 10.4646(3)   |\n| *c* (\u00c5)           | 12.173(3)    | 11.3811(3)   |\n| *\u03b1* (deg)         | 90.00        | 90.00        |\n| *\u03b2* (deg)         | 93.415(11)   | 90.00        |\n| *\u03b3* (deg)         | 90.00        | 90.00        |\n| *V* (\u00c5<sup>3</sup>) | 1278.5(4) | 1216.66(5)   |\n| *D*<sub>c</sub> (mg\u00a0m<sup>\u20113</sup>) | 1.347 | 1.333 |\n| *Z*               | 4            | 4            |\n| 2\u03b8 range          | 7.28\u2013131.94\u00b0 | 7.76\u2013131.9\u00b0  |\n| *N*<sub>ref</sub>/*N*<sub>para</sub> | 6896/352 | 2116/183 |\n| *T*  (K)           | 228(2)       | 228(2)       |\n| R<sub>1</sub> [*I*\u00a0&gt;\u00a02\u03c3(*I*)] | 0.0394 | 0.0394 |\n| *w*R<sub>2</sub>  | 0.0935       | 0.0935       |\n| GOF              | 0.988        | 0.988        |\n| abs coef.        | 0.872        | 0.843        |", "data": [[{"meta": {"name": "LISPRO", "symbol": "", "chemical formula": "C12H14LiNO5"}, "chemical formula weight": [{"value": "259.18", "unit": "", "condition": ""}], "crystal system": [{"value": "monoclinic", "condition": ""}], "space group": [{"value": "P21", "condition": ""}], "lattice parameters": [{"value": {"a": "10.3601(19)", "b": "10.1556(16)", "c": "12.173(3)", "alpha": "90.00", "beta": "93.415(11)", "gamma": "90.00"}, "condition": ""}], "cell volume": [{"value": "1278.5(4)", "unit": "\u00c5^3", "condition": ""}], "density": [{"value": "1.347", "unit": "mg/m^3", "condition": ""}]}, {"meta": {"name": "LNAPRO", "symbol": "", "chemical formula": "C11H13LiN2O4"}, "chemical formula weight": [{"value": "244.17", "unit": "", "condition": ""}], "crystal system": [{"value": "orthorhombic", "condition": ""}], "space group": [{"value": "P21212", "condition": ""}], "lattice parameters": [{"value": {"a": "10.2156(2)", "b": "10.4646(3)", "c": "11.3811(3)", "alpha": "90.00", "beta": "90.00", "gamma": "90.00"}, "condition": ""}], "cell volume": [{"value": "1216.66(5)", "unit": "\u00c5^3", "condition": ""}], "density": [{"value": "1.333", "unit": "mg/m^3", "condition": ""}]}]], "include_properties": ["chemical_formula", "chemical_formula_weight", "crystal_system", "space_group", "lattice_parameters", "cell_volume", "density"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 1. Crystallographic Data and Structure Refinement Parameters\n\n|                  | LISPRO       | LNAPRO       |\n|------------------|--------------|--------------|\n| formula          | C<sub>12</sub>H<sub>14</sub>LiNO<sub>5</sub> | C<sub>11</sub>H<sub>13</sub>LiN<sub>2</sub>O<sub>4</sub> |\n| MW               | 259.18       | 244.17       |\n| crystal system   | monoclinic   | orthorhombic |\n| space group      | *P*2<sub>1</sub> | *P*2<sub>1</sub>2<sub>1</sub>2 |\n| *a* (\u00c5)           | 10.3601(19)  | 10.2156(2)   |\n| *b* (\u00c5)           | 10.1556(16)  | 10.4646(3)   |\n| *c* (\u00c5)           | 12.173(3)    | 11.3811(3)   |\n| *\u03b1* (deg)         | 90.00        | 90.00        |\n| *\u03b2* (deg)         | 93.415(11)   | 90.00        |\n| *\u03b3* (deg)         | 90.00        | 90.00        |\n| *V* (\u00c5<sup>3</sup>) | 1278.5(4) | 1216.66(5)   |\n| *D*<sub>c</sub> (mg\u00a0m<sup>\u20113</sup>) | 1.347 | 1.333 |\n| *Z*               | 4            | 4            |\n| 2\u03b8 range          | 7.28\u2013131.94\u00b0 | 7.76\u2013131.9\u00b0  |\n| *N*<sub>ref</sub>/*N*<sub>para</sub> | 6896/352 | 2116/183 |\n| *T*  (K)           | 228(2)       | 228(2)       |\n| R<sub>1</sub> [*I*\u00a0&gt;\u00a02\u03c3(*I*)] | 0.0394 | 0.0394 |\n| *w*R<sub>2</sub>  | 0.0935       | 0.0935       |\n| GOF              | 0.988        | 0.988        |\n| abs coef.        | 0.872        | 0.843        |\n<END>", "table-categorize": "Crystal", "table-crystal-categorize": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"LISPRO\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"C12H14LiNO5\",\n        },\n        \"chemical formula weight\": [\n            {\n                \"value\": \"259.18\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n        \"crystal system\": [\n            {\n                \"value\": \"monoclinic\",\n                \"condition\": \"\",\n            },\n        ],\n        \"space group\": [\n            {\n                \"value\": \"P21\",\n                \"condition\": \"\",\n            },\n        ],\n        \"lattice parameters\": [\n            {\n                \"value\": {\n                    \"a\": \"10.3601(19)\",\n                    \"b\": \"10.1556(16)\",\n                    \"c\": \"12.173(3)\",\n                    \"alpha\": \"90.00\",\n                    \"beta\": \"93.415(11)\",\n                    \"gamma\": \"90.00\",\n                },\n                \"condition\": \"\",\n            },\n        ],\n        \"cell volume\": [\n            {\n                \"value\": \"1278.5(4)\",\n                \"unit\": \"\u00c5^3\",\n                \"condition\": \"\",\n            },\n        ],\n        \"density\": [\n            {\n                \"value\": \"1.347\",\n                \"unit\": \"mg/m^3\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"LNAPRO\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"C11H13LiN2O4\",\n        },\n        \"chemical formula weight\": [\n            {\n                \"value\": \"244.17\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n        \"crystal system\": [\n            {\n                \"value\": \"orthorhombic\",\n                \"condition\": \"\",\n            },\n        ],\n        \"space group\": [\n            {\n                \"value\": \"P21212\",\n                \"condition\": \"\",\n            },\n        ],\n        \"lattice parameters\": [\n            {\n                \"value\": {\n                    \"a\": \"10.2156(2)\",\n                    \"b\": \"10.4646(3)\",\n                    \"c\": \"11.3811(3)\",\n                    \"alpha\": \"90.00\",\n                    \"beta\": \"90.00\",\n                    \"gamma\": \"90.00\",\n                },\n                \"condition\": \"\",\n            },\n        ],\n        \"cell volume\": [\n            {\n                \"value\": \"1216.66(5)\",\n                \"unit\": \"\u00c5^3\",\n                \"condition\": \"\",\n            },\n        ],\n        \"density\": [\n            {\n                \"value\": \"1.333\",\n                \"unit\": \"mg/m^3\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n]\n```"}}, {"idx": 27, "type": "table", "classification": ["Bond & Angle"], "content": "<table-wrap id=\"tbl2\" orientation=\"portrait\" position=\"float\">\n<label>2</label>\n<caption>\n<title>LISPRO Hydrogen Bonds</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"7\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\">D</oasis:entry>\n<oasis:entry align=\"center\">H</oasis:entry>\n<oasis:entry align=\"center\">A</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(D\u2013H)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(H\u2013A)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(D\u2013A)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">D\u2013H\u2013A/deg</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>N9</oasis:entry>\n<oasis:entry>H9B</oasis:entry>\n<oasis:entry>O3</oasis:entry>\n<oasis:entry>0.91</oasis:entry>\n<oasis:entry>1.84</oasis:entry>\n<oasis:entry>2.750(6)</oasis:entry>\n<oasis:entry>178.4</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>N11</oasis:entry>\n<oasis:entry>H11A</oasis:entry>\n<oasis:entry>O10<xref rid=\"t2fn1\"></xref>\n</oasis:entry>\n<oasis:entry>0.91</oasis:entry>\n<oasis:entry>1.83</oasis:entry>\n<oasis:entry>2.744(6)</oasis:entry>\n<oasis:entry>176.6</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>N11</oasis:entry>\n<oasis:entry>H11B</oasis:entry>\n<oasis:entry>O7</oasis:entry>\n<oasis:entry>0.91</oasis:entry>\n<oasis:entry>2.01</oasis:entry>\n<oasis:entry>2.873(8)</oasis:entry>\n<oasis:entry>158.7</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>O26</oasis:entry>\n<oasis:entry>H26</oasis:entry>\n<oasis:entry>O4</oasis:entry>\n<oasis:entry>0.83</oasis:entry>\n<oasis:entry>1.92</oasis:entry>\n<oasis:entry>2.640(9)</oasis:entry>\n<oasis:entry>144.1</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>O28</oasis:entry>\n<oasis:entry>H28</oasis:entry>\n<oasis:entry>O5</oasis:entry>\n<oasis:entry>0.83</oasis:entry>\n<oasis:entry>1.82</oasis:entry>\n<oasis:entry>2.557(7)</oasis:entry>\n<oasis:entry>146.9</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"t2fn1\">\n<label>a</label>\n<p>1 + <italic toggle=\"yes\">X</italic>, +<italic toggle=\"yes\">Y</italic>, +<italic toggle=\"yes\">Z</italic>.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "Table 2. LISPRO Hydrogen Bonds\n\n| D   | H    | A  | d(D\u2013H)/\u00c5 | d(H\u2013A)/\u00c5 | d(D\u2013A)/\u00c5 | D\u2013H\u2013A/deg |\n|-----|------|----|---------|---------|---------|-----------|\n| N9  | H9B  | O3 | 0.91    | 1.84    | 2.750(6)| 178.4     |\n| N11 | H11A | O10[^a] | 0.91    | 1.83    | 2.744(6)| 176.6     |\n| N11 | H11B | O7 | 0.91    | 2.01    | 2.873(8)| 158.7     |\n| O26 | H26  | O4 | 0.83    | 1.92    | 2.640(9)| 144.1     |\n| O28 | H28  | O5 | 0.83    | 1.82    | 2.557(7)| 146.9     |\n\n[^a]: 1 + X, +Y, +Z.", "data": [["Bond & Angle type of table is not target"]], "include_properties": null, "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 2. LISPRO Hydrogen Bonds\n\n| D   | H    | A  | d(D\u2013H)/\u00c5 | d(H\u2013A)/\u00c5 | d(D\u2013A)/\u00c5 | D\u2013H\u2013A/deg |\n|-----|------|----|---------|---------|---------|-----------|\n| N9  | H9B  | O3 | 0.91    | 1.84    | 2.750(6)| 178.4     |\n| N11 | H11A | O10[^a] | 0.91    | 1.83    | 2.744(6)| 176.6     |\n| N11 | H11B | O7 | 0.91    | 2.01    | 2.873(8)| 158.7     |\n| O26 | H26  | O4 | 0.83    | 1.92    | 2.640(9)| 144.1     |\n| O28 | H28  | O5 | 0.83    | 1.82    | 2.557(7)| 146.9     |\n\n[^a]: 1 + X, +Y, +Z.\n<END>", "table-categorize": "Bond & Angle"}}, {"idx": 29, "type": "table", "classification": ["Bond & Angle"], "content": "<table-wrap id=\"tbl3\" orientation=\"portrait\" position=\"float\">\n<label>3</label>\n<caption>\n<title>LNAPRO Hydrogen Bonds</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"7\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\">D</oasis:entry>\n<oasis:entry align=\"center\">H</oasis:entry>\n<oasis:entry align=\"center\">A</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(D\u2013H)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(H\u2013A)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">\n<italic toggle=\"yes\">d</italic>(D\u2013A)/\u00c5</oasis:entry>\n<oasis:entry align=\"center\">D\u2013H\u2013A/deg</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>N5</oasis:entry>\n<oasis:entry>H5A</oasis:entry>\n<oasis:entry>O2</oasis:entry>\n<oasis:entry>0.97(2)</oasis:entry>\n<oasis:entry>1.83(2)</oasis:entry>\n<oasis:entry>2.779(2)</oasis:entry>\n<oasis:entry>163(2)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>N5</oasis:entry>\n<oasis:entry>H5B</oasis:entry>\n<oasis:entry>O1<xref rid=\"t3fn1\"></xref>\n</oasis:entry>\n<oasis:entry>0.95(3)</oasis:entry>\n<oasis:entry>1.81(3)</oasis:entry>\n<oasis:entry>2.762(2)</oasis:entry>\n<oasis:entry>176(2)</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"t3fn1\">\n<label>a</label>\n<p>\u20131/2\n\u2013 <italic toggle=\"yes\">X</italic>, 1/2 + <italic toggle=\"yes\">Y</italic>, \u22121 \u2013 <italic toggle=\"yes\">Z</italic>.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "Table 3. LNAPRO Hydrogen Bonds\n\n| D  | H   | A  | d(D\u2013H)/\u00c5 | d(H\u2013A)/\u00c5 | d(D\u2013A)/\u00c5 | D\u2013H\u2013A/deg |\n|----|-----|----|---------|---------|---------|-----------|\n| N5 | H5A | O2 | 0.97(2) | 1.83(2) | 2.779(2) | 163(2)    |\n| N5 | H5B | O1[^a] | 0.95(3) | 1.81(3) | 2.762(2) | 176(2)    |\n\n[^a]: \u20131/2 \u2013 X, 1/2 + Y, \u22121 \u2013 Z.", "data": [["Bond & Angle type of table is not target"]], "include_properties": null, "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 3. LNAPRO Hydrogen Bonds\n\n| D  | H   | A  | d(D\u2013H)/\u00c5 | d(H\u2013A)/\u00c5 | d(D\u2013A)/\u00c5 | D\u2013H\u2013A/deg |\n|----|-----|----|---------|---------|---------|-----------|\n| N5 | H5A | O2 | 0.97(2) | 1.83(2) | 2.779(2) | 163(2)    |\n| N5 | H5B | O1[^a] | 0.95(3) | 1.81(3) | 2.762(2) | 176(2)    |\n\n[^a]: \u20131/2 \u2013 X, 1/2 + Y, \u22121 \u2013 Z.\n<END>", "table-categorize": "Bond & Angle"}}, {"idx": 12, "type": "figure", "classification": null, "content": "<fig id=\"fig1\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Reaction diagrams. Reactions for LISPRO (A)\nand LNAPRO (B).</p>\n</caption>\n<graphic id=\"gr1\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0009.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 1  Reaction diagrams. Reactions for LISPRO (A) and LNAPRO (B).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 18, "type": "figure", "classification": null, "content": "<fig id=\"fig2\" orientation=\"portrait\" position=\"float\">\n<label>2</label>\n<caption>\n<p>Crystal packing\nin LISPRO and LNAPRO. Square grid network exhibited\nby LISPRO (A) and LNAPRO (B). Hydrogen atoms are removed for clarity.</p>\n</caption>\n<graphic id=\"gr2\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0010.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 2  Crystal packing in LISPRO and LNAPRO. Square grid network exhibited by LISPRO (A) and LNAPRO (B). Hydrogen atoms are removed for clarity.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 19, "type": "figure", "classification": null, "content": "<fig id=\"fig3\" orientation=\"portrait\" position=\"float\">\n<label>3</label>\n<caption>\n<p>Powder X-ray diffraction patterns of LISPRO\nand LNAPRO. Experimental\nversus calculated PXRD of LISPRO (A) and LNAPRO (B).</p>\n</caption>\n<graphic id=\"gr3\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0001.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 3  Powder X-ray diffraction patterns of LISPRO and LNAPRO. Experimental versus calculated PXRD of LISPRO (A) and LNAPRO (B).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 31, "type": "figure", "classification": null, "content": "<fig id=\"fig4\" orientation=\"portrait\" position=\"float\">\n<label>4</label>\n<caption>\n<p>LISPRO treatment\nincreases phosphorylation of GSK-3\u03b2 in adult\nrat hippocampal neural stem cells. Adult rat hippocampal neural stem\ncells (NSC, Millipore) were treated with LISPRO or LIS for 40 h in\na differentiated media. (A) Cells were lysed by RIPA buffer with protease\ncocktails and subjected to immunoblotting (WB) analysis using an antibody\nagainst phosphorylated GSK-3\u03b2 Ser9 (phosph-GSK-3\u03b2 Ser9)\nor total GSK-3\u03b2. (B) Densitometry analysis from two independent\nexperiments is represented by ratio of phosph-GSK-3\u03b2 Ser9 to\ntotal GSK-3\u03b2 band intensity under WB. <italic toggle=\"yes\">t</italic>-tests\nrevealed significant differences in ratio of phosph-GSK-3\u03b2 Ser9\nto total GSK-3\u03b2 for 1 and 5 mM of both LISPRO and LIS compared\nto control (*<italic toggle=\"yes\">p</italic> &lt; 0.05, ***<italic toggle=\"yes\">P</italic> &lt;\n0.001). These results are representative of two independent experiments\nwith <italic toggle=\"yes\">n</italic> = 2 for each condition.</p>\n</caption>\n<graphic id=\"gr4\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0002.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 4  LISPRO treatment increases phosphorylation of GSK-3\u03b2 in adult rat hippocampal neural stem cells. Adult rat hippocampal neural stem cells (NSC, Millipore) were treated with LISPRO or LIS for 40 h in a differentiated media. (A) Cells were lysed by RIPA buffer with protease cocktails and subjected to immunoblotting (WB) analysis using an antibody against phosphorylated GSK-3\u03b2 Ser9 (phosph-GSK-3\u03b2 Ser9) or total GSK-3\u03b2. (B) Densitometry analysis from two independent experiments is represented by ratio of phosph-GSK-3\u03b2 Ser9 to total GSK-3\u03b2 band intensity under WB. t-tests revealed significant differences in ratio of phosph-GSK-3\u03b2 Ser9 to total GSK-3\u03b2 for 1 and 5 mM of both LISPRO and LIS compared to control (*p < 0.05, ***P < 0.001). These results are representative of two independent experiments with n = 2 for each condition.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 33, "type": "figure", "classification": null, "content": "<fig id=\"fig5\" orientation=\"portrait\" position=\"float\">\n<label>5</label>\n<caption>\n<p>LISPRO treatment induces BDNF production by neurons. Neuroblastoma\ncells were treated with LIS and LISPRO for 48 h. BDNF was quantified\nin the media by ELISA and normalized to total protein in the cell\nlysate by BCA. <italic toggle=\"yes\">t</italic>-tests revealed significant differences\nat 1 and 10 mM for LISPRO compared to the no treatment control (*<italic toggle=\"yes\">p</italic> &lt; 0.05) and only at 10 mM for LIS (**<italic toggle=\"yes\">p</italic> &lt; 0.01). There were no statistically significant differences\nbetween LIS and LISPRO at either concentration (<italic toggle=\"yes\">p</italic> &gt; 0.05).</p>\n</caption>\n<graphic id=\"gr5\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0003.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 5  LISPRO treatment induces BDNF production by neurons. Neuroblastoma cells were treated with LIS and LISPRO for 48 h. BDNF was quantified in the media by ELISA and normalized to total protein in the cell lysate by BCA. t-tests revealed significant differences at 1 and 10 mM for LISPRO compared to the no treatment control (*p < 0.05) and only at 10 mM for LIS (**p < 0.01). There were no statistically significant differences between LIS and LISPRO at either concentration (p > 0.05).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 35, "type": "figure", "classification": null, "content": "<fig id=\"fig6\" orientation=\"portrait\" position=\"float\">\n<label>6</label>\n<caption>\n<p>LISPRO treatment abolishes\nNO production in LPS-activated microglia.\nBV2 microglia were pretreated with LIS and LISPRO at 25 and 12.5 mM\nfor 1 h prior to being activated by the addition of 100 ng/mL LPS.\nEighteen hours later, media was collected and NO was measured. The\nno treatment, no LPS control group produced very low (basal) levels\nof NO. The no treatment with LPS control group produced the highest\nlevels of NO. The lithium treatments abolished NO production at 25\nmM and reduced it at 12.5 mM with LISPRO being advantageous at this\nconcentration. Statistical significance from the no treatment with\nLPS control was assessed by <italic toggle=\"yes\">t</italic>-tests (*<italic toggle=\"yes\">p</italic> &lt; 0.05, **<italic toggle=\"yes\">p</italic> &lt; 0.01, ***<italic toggle=\"yes\">p</italic> &lt; 0.001).</p>\n</caption>\n<graphic id=\"gr6\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0004.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 6  LISPRO treatment abolishes NO production in LPS-activated microglia. BV2 microglia were pretreated with LIS and LISPRO at 25 and 12.5 mM for 1 h prior to being activated by the addition of 100 ng/mL LPS. Eighteen hours later, media was collected and NO was measured. The no treatment, no LPS control group produced very low (basal) levels of NO. The no treatment with LPS control group produced the highest levels of NO. The lithium treatments abolished NO production at 25 mM and reduced it at 12.5 mM with LISPRO being advantageous at this concentration. Statistical significance from the no treatment with LPS control was assessed by t-tests (*p < 0.05, **p < 0.01, ***p < 0.001).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 37, "type": "figure", "classification": null, "content": "<fig id=\"fig7\" orientation=\"portrait\" position=\"float\">\n<label>7</label>\n<caption>\n<p>LISPRO induces neuronal differentiation of stem\ncells. Adult rat\nhippocampal neural stem cells were cultured with neurobasal media\nonly (A), neurobasal media with 3 mM LIS (B), and neurobasal media\nwith 3 mM LISPRO (C). Blue DAPI staining indicates nuclei, red GFAP\nstaining indicates astrocytes, and green Tuj1 indicates neurons.</p>\n</caption>\n<graphic id=\"gr7\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0005.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 7  LISPRO induces neuronal differentiation of stem cells. Adult rat hippocampal neural stem cells were cultured with neurobasal media only (A), neurobasal media with 3 mM LIS (B), and neurobasal media with 3 mM LISPRO (C). Blue DAPI staining indicates nuclei, red GFAP staining indicates astrocytes, and green Tuj1 indicates neurons.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 39, "type": "figure", "classification": null, "content": "<fig id=\"fig8\" orientation=\"portrait\" position=\"float\">\n<label>8</label>\n<caption>\n<p>\n<italic toggle=\"yes\">In vivo</italic> plasma and brain pharmacokinetics of LISPRO\nand Li<sub>2</sub>CO<sub>3</sub>. Male rats (<italic toggle=\"yes\">n</italic> =\n3 per formulation per time point) were dosed with 4 mEq/kg of lithium\nvia oral gavage as LISPRO or Li<sub>2</sub>CO<sub>3</sub>. Plasma\nand brain lithium levels were determined at 2, 24, 48, and 72 h by\natomic absorption spectrometry. (A) Li<sub>2</sub>CO<sub>3</sub> plasma\nlithium concentration versus time (mean \u00b1 SEM). (B) Li<sub>2</sub>CO<sub>3</sub> brain lithium per gram of wet weight versus time (mean\n\u00b1 SEM). (C) LISPRO plasma lithium concentration versus time (mean\n\u00b1 SEM). (D) LISPRO brain lithium per gram of wet weight versus\ntime (mean \u00b1 SEM). (E) Compilation plasma lithium concentration\nversus time (mean \u00b1 SEM). (F) Compilation brain lithium concentration\nversus time (mean \u00b1 SEM).</p>\n</caption>\n<graphic id=\"gr8\" orientation=\"portrait\" position=\"float\" xlink:href=\"mp-2013-00571a_0006.tif\" xlink:type=\"simple\"></graphic>\n</fig>", "clean_text": " 8   In vivo plasma and brain pharmacokinetics of LISPRO and Li2CO3. Male rats (n = 3 per formulation per time point) were dosed with 4 mEq/kg of lithium via oral gavage as LISPRO or Li2CO3. Plasma and brain lithium levels were determined at 2, 24, 48, and 72 h by atomic absorption spectrometry. (A) Li2CO3 plasma lithium concentration versus time (mean \u00b1 SEM). (B) Li2CO3 brain lithium per gram of wet weight versus time (mean \u00b1 SEM). (C) LISPRO plasma lithium concentration versus time (mean \u00b1 SEM). (D) LISPRO brain lithium per gram of wet weight versus time (mean \u00b1 SEM). (E) Compilation plasma lithium concentration versus time (mean \u00b1 SEM). (F) Compilation brain lithium concentration versus time (mean \u00b1 SEM).   ", "data": null, "include_properties": null, "intermediate_step": {}}], "metadata": {"doi": "10.1021/mp400571a", "title": "\nImproving Lithium Therapeutics by Crystal Engineering\nof Novel Ionic Cocrystals\n", "journal": "American\nChemical\nSociety", "date": "2013.11", "author_list": ["Smith\nAdam J.", "Kim\nSeol-Hee", "Duggirala\nNaga K.", "Jin\nJingji", "Wojtas\nLukasz", "Ehrhart\nJared", "Giunta\nBrian", "Tan\nJun", "Zaworotko\nMichael\nJ.", "Shytle\nR. Douglas"]}}